<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55637</article-id><article-id pub-id-type="doi">10.7554/eLife.55637</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-153716"><name><surname>Uehara</surname><given-names>Hironori</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6133-4918</contrib-id><email>uhironori0916@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2809"><name><surname>Zhang</surname><given-names>Xiaohui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179430"><name><surname>Pereira</surname><given-names>Felipe</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179431"><name><surname>Narendran</surname><given-names>Siddharth</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179432"><name><surname>Choi</surname><given-names>Susie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179433"><name><surname>Bhuvanagiri</surname><given-names>Sai</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179434"><name><surname>Liu</surname><given-names>Jinlu</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179435"><name><surname>Ravi Kumar</surname><given-names>Sangeetha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179436"><name><surname>Bohner</surname><given-names>Austin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179437"><name><surname>Carroll</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2813"><name><surname>Archer</surname><given-names>Bonnie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179438"><name><surname>Zhang</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179439"><name><surname>Liu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2824"><name><surname>Gao</surname><given-names>Guangping</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179440"><name><surname>Ambati</surname><given-names>Jayakrishna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40130"><name><surname>Jun</surname><given-names>Albert S</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-2593"><name><surname>Ambati</surname><given-names>Balamurali K</given-names></name><email>bambati@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon</institution><addr-line><named-content content-type="city">Eugene, OR</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Ophthalmology, University of Virginia</institution><addr-line><named-content content-type="city">Charlottesville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Division of Epidemiology, Department of Internal Medicine, University of Utah</institution><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Gene Therapy Center, Department of Microbiology and Physiological Science Systems, University of Massachusetts Medical School</institution><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Wilmer Eye Institute, Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Zoghbi</surname><given-names>Huda Y</given-names></name><role>Senior Editor</role><aff><institution>Texas Children's Hospital</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Cepko</surname><given-names>Constance L</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e55637</elocation-id><history><date date-type="received" iso-8601-date="2020-01-31"><day>31</day><month>01</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-06-07"><day>07</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Uehara et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Uehara et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55637-v2.pdf"/><abstract><p>A missense mutation of collagen type VIII alpha 2 chain (<italic>COL8A2</italic>) gene leads to early-onset Fuchs’ endothelial corneal dystrophy (FECD), which progressively impairs vision through the loss of corneal endothelial cells. We demonstrate that CRISPR/Cas9-based postnatal gene editing achieves structural and functional rescue in a mouse model of FECD. A single intraocular injection of an adenovirus encoding both the Cas9 gene and guide RNA (Ad-Cas9-Col8a2gRNA) efficiently knocked down mutant <italic>COL8A2</italic> expression in corneal endothelial cells, prevented endothelial cell loss, and rescued corneal endothelium pumping function in adult <italic>Col8a2</italic> mutant mice. There were no adverse sequelae on histology or electroretinography. <italic>Col8a2</italic> start codon disruption represents a non-surgical strategy to prevent vision loss in early-onset FECD. As this demonstrates the ability of Ad-Cas9-gRNA to restore the phenotype in adult post-mitotic cells, this method may be widely applicable to adult-onset diseases, even in tissues affected with disorders of non-reproducing cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Fuchs endothelial corneal dystrophy</kwd><kwd>CRISPR/Cas9</kwd><kwd>Adenovirus</kwd><kwd>off-target analysis of CRISPR/Cas9</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01EY017950</award-id><principal-award-recipient><name><surname>Ambati</surname><given-names>Balamurali K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ambati</surname><given-names>Balamurali K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>EY017950</award-id><principal-award-recipient><name><surname>Ambati</surname><given-names>Balamurali K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Adenoviral CRISPR/Cas9 gene knockdown of mutant Col8a2 achieves structural and functional rescue of murine Fuchs’ endothelial corneal dystrophy, the first demonstration of post-mitotic CRISPR-based knockdown for phenotypic restoration.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Fuchs’ endothelial corneal dystrophy (FECD), which is characterized by progressive loss of corneal endothelial cells, is the leading cause of corneal transplantation in industrialized societies (<xref ref-type="bibr" rid="bib9">EBAA, 2016</xref>). Currently, the only available treatment for advanced FECD is corneal transplantation, which entails significant risks (e.g., infection, hemorrhage, rejection, glaucoma) both during surgery and during the lifetime of the patient (<xref ref-type="bibr" rid="bib21">Mitry et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Sugar et al., 2015</xref>). A missense mutation of the collagen 8A2 (<italic>COL8A2</italic>) gene in humans causes early-onset Fuchs’ dystrophy (<xref ref-type="bibr" rid="bib10">Gottsch et al., 2005</xref>; <xref ref-type="bibr" rid="bib4">Biswas et al., 2001</xref>; <xref ref-type="bibr" rid="bib32">Vedana et al., 2016</xref>). Although other mutations within the <italic>ZEB1/TCF8</italic> locus and <italic>TCF4</italic> trinucleotide repeats are associated with Fuchs’ dystrophy (<xref ref-type="bibr" rid="bib27">Riazuddin et al., 2010</xref>; <xref ref-type="bibr" rid="bib12">Igo et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Aldave et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Stamler et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Nanda et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Mootha et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Nakano et al., 2015</xref>; <xref ref-type="bibr" rid="bib1">Afshari et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Kuot et al., 2017</xref>), only the <italic>Col8a2</italic> missense mutant mouse has successfully recapitulated its key features. Two distinct transgenic approaches in mice have helped illuminate the role of <italic>Col8a2</italic> in the onset of FECD. Knockout mice lacking <italic>Col8a2</italic> alone or combined with a homozygous <italic>Col8a1</italic> knockout mutation do not develop FECD (<xref ref-type="bibr" rid="bib11">Hopfer et al., 2005</xref>). Although the double knockouts exhibited corneal biomechanical weakening (without endothelial loss), <italic>Col8a2</italic> knockouts showed no apparent phenotype. In contrast, <italic>Col8a2</italic> mutant knock-in mice carrying the Q455K and L450W mutations associated with early-onset FECD in human patients displayed corneal endothelial excrescences known as guttae, as well as the endothelial cell loss, which are hallmarks of human FECD (<xref ref-type="bibr" rid="bib20">Meng et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Jun et al., 2012</xref>). Taken together, these studies suggest that COL8A2 protein is not essential to corneal function, yet is causally responsible for FECD via mutant dominant gain-of-function activity. We, therefore, sought to test whether knockdown of mutant <italic>COL8A2</italic> could offer a new therapeutic strategy for early-onset FECD, establishing a precedent for treating gain-of-function genetic disorders in post-mitotic cells by tissue-specific ablation of the missense gene, targeting the start codon with CRISPR/Cas9.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Strategy of mouse Col8a2 gene knockdown by CRISPR/Cas9</title><p>To disrupt <italic>Col8a2</italic> gene expression, we designed a guide RNA (gRNA) targeting the start codon of the <italic>Col8a2</italic> gene (MsCol8a2gRNA) by non-homologous end-joint repair through CRISPR/Cas9 (<xref ref-type="bibr" rid="bib18">Mali et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Cong et al., 2013</xref>; <xref ref-type="fig" rid="fig1">Figure 1a</xref>). The strategy of targeting the start codon is sufficient for blocking gene expression at the translational level. The appeal of this strategy, as opposed to correcting the mutation through homologous recombination (HR), is that poor efficiency of CRISPR-based HR would result in a majority of sequence changes comprising insertions/deletions (indels). Consequently, the farther one targets downstream from the start codon, the greater the risk of missense mutations that result in viable mutant proteins with unknown activity. By targeting inside or near the start codon, this risk is minimized. As a backbone plasmid, we used pX330-U6-Chimeric_BB-CBh-hSpCas9 (<xref ref-type="bibr" rid="bib7">Cong et al., 2013</xref>), which encodes spCas9 and gRNA downstream of the U6 promoter (px330-MsCol8a2gRNA1). To detect the indel, we used CviAII or Hin1II digestion of PCR products (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). CviAII/Hin1II cuts 5’-CATG-3’, which digests at the <italic>Col8a2</italic> start codon, whereas an undigested band indicates the presence of an indel at the start codon. As expected, px330-MsCol8a2gRNA1 creates an indel in mouse NIH3T3 cells (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). Furthermore, we designed MsCol8a2gRNA2 and MsCol8a2gRNA3 downstream of MsCol8a2gRNA1 (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). Co-transfection of px330-MsCol8a2gRNA1 with px330-MsCol8a2gRNA2 or px330-MsCol8a2gRNA3 resulted in an extra PCR band (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). The indels by px330-MsCol8A2gRNA1 were confirmed by sequencing (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). Although two gRNAs could potentially attenuate target gene expression more efficiently than a single gRNA, we proceeded with in vivo experiments using only MsCol8a2gRNA1.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Design of <italic>Col8a2</italic> guide RNA and indel confirmation in vitro.</title><p>(<bold>a</bold>) Design of guide RNAs (gRNAs) for mouse <italic>Col8a2</italic> gene and the schematic diagram of indel detection by restriction enzyme digestion of the PCR product. gRNA1, which is used for Ad-Cas9-Col8a2gRNA, was designed to disrupt the <italic>Col8a2</italic> start codon. PCR primers were designed to flank the start codon and gRNA-targeting sites. PCR product from the intact DNA sequence was of 560 bp, which was digested to 303 bp, 131 bp, and 126 bp by CviAII/Hin1II restriction enzymes. (<bold>b</bold>) In px330-gRNA1-transfected NIH3T3 cells, the PCR product showed an extra band (~430 bp, arrow) after CviAII digestion. pMax-GFP was used as a control. (<bold>c</bold>) A combination of two plasmids (px330-gRNA1 + px330-gRNA2 and px330-gRNA1 + px330-gRNA2) yields lower bands (arrow), reflecting the deletion between the targeted sites. (<bold>d</bold>) Deletion of the start codon by px330-gRNA1 was confirmed by Sanger sequencing after cloning.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>In vivo Col8a2 gene knockdown in mouse corneal endothelium by adenovirus-mediated CRISPR/Cas9</title><p>To introduce the genes (SpCas9 and gRNA) into corneal endothelium in vivo, we produced recombinant adenovirus Cas9-Col8a2gRNA (Ad-Cas9-Col8a2gRNA). There are several common viruses such as adeno-associated virus and lentivirus, but previous studies have indicated that only adenovirus demonstrates efficient gene transfer to corneal endothelium, in vivo. In fact, we found adenovirus-GFP showed efficient green fluorescent protein (GFP) expression in corneal endothelium (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). First, we determined the effective adenovirus dose in vitro, for indel production at the <italic>Col8a2</italic> start codon (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–c</xref>). To confirm effective indel production in vivo, we tested various titers of Ad-Cas9-Col8a2gRNA injected into the aqueous humor of adult C57BL/6J mice. After 1 month, the corneal endothelium/stroma and epithelium/stroma were separated mechanically (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a–h</xref>), followed by genomic DNA (gDNA) purification. Digestion of PCR products by CviAII/Hin1II revealed an undigested band from amplified corneal endothelium DNA (arrow in <xref ref-type="fig" rid="fig2">Figure 2b</xref>), indicating disruption of the <italic>Col8a2</italic> start codon, which was confirmed by Sanger sequence analysis (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). In contrast, corneal epithelium and stroma revealed an intact start codon after CviAII/Hin1II digestion of PCR-amplified DNA. Further, the genome of Ad-Cas9-Col8a2gRNA was detected from corneal endothelium but not corneal epithelium/stroma (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). This strongly suggests that the anterior chamber injection of Ad-Cas9-Col8a2gRNA induces indels in the corneal endothelium but not in the epithelium or stroma.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Intracameral injection of Ad-Cas9-Col8a2gRNA1 induces indel at the Col8a2 start codon in corneal endothelium.</title><p>(<bold>a</bold>) Adenovirus infection to corneal endothelium via intracameral injection was confirmed by adenovirus GFP. Top: whole mouse cornea flatmount. Bottom: the magnified section of the image. (<bold>b</bold>) Ad-Cas9-Col8a2gRNA1 induced an insertion/deletion (indel) at the <italic>Col8a2</italic> start codon in the corneal endothelium but not in the corneal epithelium/stroma. Genomic DNA of corneal endothelium/stroma and corneal epithelium/stroma was PCR amplified with primers flanking the <italic>Col8a2</italic> start site and digested with CviAII, which recognizes the intact <italic>Col8a2</italic> start codon (5’-CATG-3’). The CviAII undigested band (arrow) demonstrates the indel at the <italic>Col8a2</italic> start codon. (<bold>c</bold>) Sanger sequencing of the cloned PCR product from genomic DNA purified from corneal endothelium/stroma confirming indels at the <italic>Col8a2</italic> start codon.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Ad-Cas9-Col8a2gRNA cloning and its indel activity in vitro.</title><p>(<bold>a</bold>) Cloning of Ad-Cas9-Col8a2gRNA by its indel activity in AD293 cells. The method was the same as described for <xref ref-type="fig" rid="fig1">Figure 1</xref>. The extra band (arrow) demonstrates the indel at the start codon. We examined 30 different clones and found only one clone with indel activity. (<bold>b</bold>) As Ad-Cas9-Col8a2gRNA titer increased, indel activity also increased. (<bold>c</bold>) Results from Sanger sequencing of cloned PCR products.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Procedure of peeling off mouse corneal endothelium.</title><p>Mouse corneal endothelium was peeled off mechanically. (<bold>a</bold>) Mouse cornea after excision from the rest of the eye. (<bold>b</bold>) Mouse cornea was stained with 0.4% trypan blue for visualization, and the limbus/sclera was removed. (<bold>c–e</bold>) Mechanical peeling of corneal endothelium. (<bold>f</bold>) Epithelium/stroma and stroma/endothelium after complete separation. (<bold>g, h</bold>) Cryosection image of the cornea with endothelium peeled. 4′,6-diamidino-2-phenylindole (DAPI) staining showed incomplete separation of corneal endothelium and stroma.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Adenovirus genome was detected in corneal endothelium but not epithelium.</title><p>1 week following adenovirus injection, we purified DNA from corneal endothelium and epithelium/stroma, respectively. Then, PCR was conducted using primers to detect Cas9.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig2-figsupp3-v2.tif"/></fig></fig-group><p>Next, to examine whether start codon disruption reduces COL8A2 protein expression in the corneal endothelium, we measured the localized protein in sectioned corneas with an anti-COL8A2 antibody (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a</xref>). The non-injected cornea showed COL8A2 protein expression in corneal epithelium and endothelium. As predicted, Ad-Cas9-Col8a2gRNA-injected corneas exhibited reduced COL8A2 protein expression in corneal endothelium but not corneal epithelium. Furthermore, we measured the intensity of COL8A2 staining in corneal endothelium and epithelium (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b–c</xref>). The intensity of isotype control was subtracted as a background. While the epithelium layer did not show any significant difference, the intensity of COL8A2 staining in corneal endothelium layer significantly decreased at 0.63 × 10<sup>7</sup> vg and 0.25 × 10<sup>8</sup> vg of Ad-Cas9-Col8a2gRNA compared to the no-injection control. Thus, we successfully knocked down in vivo COL8A2 protein expression in adult corneal endothelium by Ad-Cas9-Col8a2gRNA.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ad-Cas9-Col8a2gRNA reduces <italic>COL8A2</italic> expression in mouse corneal endothelium but not epithelium.</title><p><italic>COL8A2</italic> protein immunostaining from the cornea 2 months after injection with Dulbecco’s phosphate-buffered saline (DPBS) (4 µl, upper figures) or Ad-Cas9-Col8a2gRNA (0.63 × 10<sup>7</sup> vg in 4 µl, lower figures). In Ad-Cas9-Col8a2gRNA-injected corneas, lower COL8A2 protein expression was seen in corneal endothelium, but not in epithelium. Epi: epithelium, Str: stroma, En (arrow): endothelium. Scale bar = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>COL8A2 reduction in corneal endothelium is correlated with the amount of Ad-Cas9-Col8a2gRNA.</title><p>(<bold>a</bold>) COL8A2 immunostaining in each amount of Ad-Cas9-Col8a2gRNA injection. (<bold>b</bold>) COL8A2 expression in corneal endothelium and corneal epithelium was quantified from the images. The staining intensity in isotype control was subtracted as a background. (<bold>c</bold>) The ratio of COL8A2 staining between corneal endothelium and epithelium. *p&lt;0.01 by Student’s t-test. The source data is Figure3-figure supplement1_source data.xlsx.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>COL8A2 staining intensity.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Determination of the safety dose of Ad-Cas9-Col8a2gRNA</title><p>As adenoviruses are known to induce inflammation and cell toxicity, we tested a range of Ad-Cas9-Col8a2gRNA titers for safety. Corneal transparency, corneal thickness, and histopathology appeared normal at low titers (<xref ref-type="fig" rid="fig4">Figure 4a–d</xref>), and ZO-1 immunolabeling detected reduced endothelial density in corneal flat mounts after injecting 1.0 × 10<sup>8</sup> vg (<xref ref-type="fig" rid="fig4">Figure 4e–f</xref>). A higher titer (4.0 × 10<sup>8</sup> vg) devastated the mouse corneal endothelium, inducing corneal opacity and edema in C57BL/6J mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). At 0.25 × 10<sup>8</sup> vg, neither tumor necrosis factor alpha (TNFα) nor interferon gamma (IFNγ) was upregulated 4 weeks after Ad-Cas9-Col8a2gRNA injection (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Moreover, we confirmed that Ad-Cas9-Col8a2gRNA did not suppress retinal function, as monitored by electroretinography (ERG), or damage the retinal structure, as visualized by hematoxylin-eosin (HE) staining (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplements 3</xref> and <xref ref-type="fig" rid="fig4s4">4a</xref>). Finally, anterior chamber injection of Ad-Cas9-Col8a2gRNA did not induce liver or kidney damage or inflammation, as visualized by HE staining of hepatic and renal tissues (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4b</xref>). Hence, subsequent experiments were performed with 0.25 × 10<sup>8</sup> vg of Ad-Cas9-Col8a2gRNA, which did not induce detectable toxicity.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Low doses of Ad-Cas9-Col8a2gRNA did not show toxicity.</title><p>(<bold>a</bold>) Injection of Ad-Cas9-Col8a2gRNA at 0.63 × 10<sup>7</sup>, 0.25 × 10<sup>8</sup>, and 1.0 × 10<sup>8</sup> vg did not result in corneal edema or opacity. (<bold>b</bold>) Representative corneal optical coherence tomography (OCT) images captured by Heidelberg Spectralis microscope with/without Ad-Cas9-Col8a2gRNA injection. (<bold>c</bold>) The average of central corneal thickness in each condition. Significant differences among groups were not observed (analysis of variance (ANOVA), p = 0.78). n = 8–12. Error bars show standard deviation. (<bold>d</bold>) Hematoxylin-eosin (HE), Periodic Acid-Schiff (PAS), and trichrome Masson staining showed no apparent phenotypes in Ad-Cas9-Col8A2gRNA-injected corneas compared to non-injected corneas. Scale bar = 50 µm. (<bold>e</bold>) Representative images of corneal flat mounts immunolabeled with ZO-1 antibody for each condition. Scale bar = 100 µm. (<bold>f</bold>) Average corneal endothelium densities. 1.0 × 10<sup>8</sup> vg Ad-Cas9-Col8A2gRNA reduced corneal endothelium density significantly; n = 6–9. *p&lt;0.001 by Student’s t-test. Error bars show standard deviation. The source data is (<bold>c</bold>) Figure4-source data 1.xlsx and (<bold>f</bold>) Figure4-source data 2.xlsx.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Central corneal thickness.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Corneal endothelial cell density.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig4-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>High levels of Ad-Cas9-Col8a2gRNA (4 × 10<sup>8</sup>) are toxic to corneal endothelium in C57BL/6J mice.</title><p>2 weeks following intracameral injection of Dulbecco’s phosphate-buffered saline (DPBS) or Ad-Cas9-Col8a2gRNA (4 × 10<sup>8</sup> vg), corneas were harvested to examine endothelial integrity with anti-ZO-1 antibody. This high titer of Ad-Cas9-Col8a2gRNA led to widespread devastation of the corneal endothelium. Scale bar = 200 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Intracameral injection of 0.25 × 10<sup>8</sup> Ad-Cas9-Col8a2gRNA does not show significant induction of inflammation markers.</title><p>Tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) were stained 4 weeks post Ad-GFP, Ad-Cas9-Col8a2gRNA, or concanavalin A (1 μg) intravitreal injection. Scale bar is 100 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Ad-Cas9-Col8a2gRNA does not induce retinal disfunction.</title><p>Dark-adapted electroretinography (ERG) was used for evaluation of retinal function. (<bold>a</bold>) Representative ERG of no treatment (prior to injection), Ad-GFP (anterior chamber injection), Ad-Cas9-Col8a2gRNA (anterior chamber injection), and concanavalin A (intravitreal injection). Intravitreal injection of concanavalin A was used as a positive control by inducing retinal inflammation. (<bold>b, c</bold>) a-wave of no treatment and each treatment 2 and 4 weeks post injection. We used three different stimulus light intensities (−1.7,–0.8, and 1 log cd.s/m<sup>2</sup>). (<bold>d, e</bold>) b-wave of no treatment and each treatment 2 and 4 weeks post injection. n = 14 (no treatment), 6 (Ad-GFP), 6 (Ad-Cas9-Col8a2gRNA), and 2 (concanavalin A, 1 μg). *p&lt;0.05 and **p&lt;0.01 by Student’s t-test compared to no-treatment control. The source data is Figure4-figure supplement3_source data.xlsx.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>ERG.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig4-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Anterior chamber injection of 0.25 × 10<sup>8</sup> Ad-Cas9-Col8a2gRNA does not show retina, liver, and kidney toxicity.</title><p>4 weeks post injection, we observed each tissue by hematoxylin-eosin (HE) staining. (<bold>a</bold>) Retina. Scale bar is 100 μm. (<bold>b</bold>) Liver and kidney. Scale bar is 400 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig4-figsupp4-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Efficiency of indel induction by Ad-Cas9-Col8a2gRNA in vivo</title><p>To determine the indel rate in mouse corneal endothelium, we performed deep sequencing of PCR products (including the target site) amplified from gDNA of corneal endothelium. We found that the indel rate was 23.7 ± 4.5% in mouse corneal endothelium (<xref ref-type="table" rid="table1">Table 1</xref>). Most insertions were 1 bp insertions (19.8 ± 4.0% in total reads, <xref ref-type="fig" rid="fig5">Figure 5a</xref>), while 2 bp deletions were the most frequent (1.0 ± 0.3% in total reads, <xref ref-type="fig" rid="fig5">Figure 5b</xref>). We, moreover, found that A or T insertion was predominant, with the proportion of A:T:G:C being 48.7:44.6:1.8:4.9 (<xref ref-type="table" rid="table2">Table 2</xref>). Adenine insertion (9.4 ± 1.9% in total reads) produced a cryptic ATG start codon (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). This insertion changes G to C at the −3 position (A in ATG as +1). Since previous studies have indicated that G or A at the −3 position is important for translational commencement, which is known as a Kozak sequence (<xref ref-type="bibr" rid="bib15">Kozak, 1984</xref>; <xref ref-type="bibr" rid="bib28">Rual et al., 2004</xref>), a consequent reduction in protein expression by the disruption of Kozak/ATG sequence would be predicted.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Distribution of inserted and deleted residue number.</title><p>(<bold>a</bold>) Frequency of insertion. 1 bp insertion was most frequent. (<bold>b</bold>) Frequency of deletion. 2 bp deletion was most frequent. n = 4. Error bar represents standard deviation. The source data is Figure5-source data.xlsx.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Counts of insertion/deletion.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Single adenine insertion at the mouse <italic>Col8a2</italic> start codon.</title><p>An adenine insertion produced a cryptic ATG codon that resulted in disruption of Kozak sequence (G to C at −3 position).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig5-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Indel rate at mouse <italic>Col8a2</italic> target site by Ad-Cas9-Col8a2gRNA from corneal endothelium.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Indel rate in <italic>Col8a2</italic> gene.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-table1-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Total read</th><th valign="bottom">No change</th><th valign="bottom">Insertion</th><th valign="bottom">Deletion</th><th valign="bottom">Indel</th></tr></thead><tbody><tr><td rowspan="2">Cornea1</td><td rowspan="2">87,554</td><td valign="bottom">68,228</td><td valign="bottom">16,378</td><td valign="bottom">2948</td><td valign="bottom">19,326</td></tr><tr><td>(77.9%)</td><td>(18.7%)</td><td>(3.4%)</td><td>(22.1%)</td></tr><tr><td rowspan="2">Cornea2</td><td rowspan="2">97,749</td><td valign="bottom">69,455</td><td valign="bottom">24,202</td><td valign="bottom">4092</td><td valign="bottom">28,294</td></tr><tr><td>(77.1%)</td><td>(24.8%)</td><td>(4.2%)</td><td>(28.9%)</td></tr><tr><td rowspan="2">Cornea3</td><td rowspan="2">87,908</td><td valign="bottom">71,664</td><td valign="bottom">13,508</td><td valign="bottom">2736</td><td valign="bottom">16,244</td></tr><tr><td>(81.5%)</td><td>(24.8%)</td><td>(3.1%)</td><td>(18.5%)</td></tr><tr><td rowspan="2">Cornea4</td><td rowspan="2">93,234</td><td valign="bottom">69,747</td><td valign="bottom">19,831</td><td valign="bottom">3656</td><td valign="bottom">23,487</td></tr><tr><td>(74.8%)</td><td>(21.3%)</td><td>(3.9%)</td><td>(25.2%)</td></tr><tr><td colspan="2">Average of ratio</td><td>76.3 ± 4.5%</td><td>20.0 ± 4.0%</td><td>3.6 ± 0.5%</td><td>23.7 ± 4.5%</td></tr></tbody></table><table-wrap-foot><fn><p>The source data is Table1-source data.xlsx.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Ratio of A:T:G:C in 1 bp insertions.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Number of inserted DNA residues.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-table2-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th valign="bottom">Total read number of single insertions in the start codon (between A and T)</th><th>A</th><th>T</th><th>G</th><th>C</th></tr></thead><tbody><tr><td valign="bottom">Cornea1</td><td valign="bottom">15,655</td><td valign="bottom">7925 <break/>(50.6%)</td><td valign="bottom">6703 <break/>(42.8%)</td><td valign="bottom">230 <break/>(1.5%)</td><td valign="bottom">797 <break/>(5.1%)</td></tr><tr><td valign="bottom">Cornea2</td><td valign="bottom">23,315</td><td valign="bottom">10,877 <break/>(46.7%)</td><td valign="bottom">10,890 <break/>(46.7%)</td><td valign="bottom">294 <break/>(1.3%)</td><td valign="bottom">1254 <break/>(5.4%)</td></tr><tr><td valign="bottom">Cornea3</td><td valign="bottom">13,083</td><td valign="bottom">6035 <break/>(46.1%)</td><td valign="bottom">6013 <break/>(46.0%)</td><td valign="bottom">320 <break/>(2.4%)</td><td valign="bottom">715 <break/>(5.5%)</td></tr><tr><td valign="bottom">Cornea4</td><td valign="bottom">18,829</td><td valign="bottom">9706 <break/>(51.5%)</td><td valign="bottom">8088 <break/>(43.0%)</td><td valign="bottom">356 <break/>(1.9%)</td><td valign="bottom">679 <break/>(3.6%)</td></tr><tr><td colspan="2" valign="bottom">Average of ratio</td><td valign="bottom">48.7 ± 2.7%</td><td valign="bottom">44.6 ± 2.0%</td><td valign="bottom">1.8 ± 0.5%</td><td valign="bottom">4.9 ± 0.9%</td></tr></tbody></table><table-wrap-foot><fn><p>The source data is Table2-source data.xlsx.</p></fn></table-wrap-foot></table-wrap><p>The indel rate in corneal endothelium was 23.7 ± 4.5%, which was much lower than anticipated since COL8A2 protein expression in mouse corneal endothelium was markedly decreased by the anterior chamber injection of Ad-Cas9-Col8a2gRNA (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) and because of the high rate of adenovirus infection of the corneal endothelium (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). We speculate this is due to gDNA from corneal stroma cells based on the following. The number of corneal endothelial cells is approximately 7200 cells (2300 cells/mm<sup>2</sup> x 1 mm x 1 mm x π), with an expected purified gDNA amount of 43 ng as the genome mass from mouse cell is 6 pg ((5.46 x 10<sup>9</sup> as 2n) x 660 (average molecular weight of DNA base pair)/(6.02 x 10<sup>−23</sup>, Avogadro’s number)). The purified gDNA from the peeled endothelium was higher than predicted (<xref ref-type="table" rid="table3">Table 3</xref>). We, therefore, hypothesized that stromal cells were contained in our samples. To confirm this, we conducted experiments as described in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. We peeled half of corneal endothelium, placed back in situ, and then proceeded to cryosection with 4′,6-diamidino-2-phenylindole (DAPI) staining. As expected, we found stroma cells along with corneal endothelial cells. Hence, we deduced that the extra gDNA is stromal-derived. Therefore, we can normalize indel rate by the proportion of endothelial cell gDNA to total isolated gDNA (<xref ref-type="table" rid="table3">Table 3</xref>). From this calculation, the normalized indel rate (proportion of endothelial cells with indels) is 102.5 ± 16.3%. This corroborates with the observed immunostaining pattern in <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Normalized indel rate by the purified genomic DNA amount.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th valign="bottom">Concentration (ng/ul)</th><th valign="bottom">gDNA amount (ng, 16 ul elution)</th><th valign="bottom">Cell number from gDNA amount</th><th valign="bottom">Intact indel rate (%)</th><th valign="bottom">Normalized indel rate (%)</th></tr></thead><tbody><tr><td valign="bottom">Cornea1</td><td valign="bottom">14.5</td><td valign="bottom">232</td><td valign="bottom">38,744</td><td valign="bottom">22.1</td><td valign="bottom">118.6</td></tr><tr><td valign="bottom">Cornea2</td><td valign="bottom">10.5</td><td valign="bottom">168</td><td valign="bottom">28,056</td><td valign="bottom">28.9</td><td valign="bottom">112.3</td></tr><tr><td valign="bottom">Cornea3</td><td valign="bottom">12</td><td valign="bottom">192</td><td valign="bottom">32,064</td><td valign="bottom">18.5</td><td valign="bottom">82.1</td></tr><tr><td valign="bottom">Cornea4</td><td valign="bottom">10.4</td><td valign="bottom">166.4</td><td valign="bottom">27,789</td><td valign="bottom">25.2</td><td valign="bottom">97.0</td></tr></tbody></table></table-wrap><p>To understand the relationship between Cas9/gRNA expression and Col8a2 expression, we measured Cas9 and gRNA expression 1 week following injection of Ad-Cas9-Col8a2gRNA by real-time reverse transcription-PCR (RT-PCR). We found that Cas9 and gRNA expressions were high at 0.63 × 10<sup>7</sup> and 2.5 × 10<sup>7</sup> vg (<xref ref-type="fig" rid="fig6">Figure 6a–b</xref>) and that these doses of Ad-Cas9-Col8a2gRNA demonstrated a significant decrease of COL8A2 in corneal endothelium as shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. Furthermore, to determine the indel rate, we designed two sets of primers for the <italic>Col8a2</italic> mRNA. One set was designed at the unrelated position of gRNA target. This set of primers detects total <italic>Col8a2</italic> mRNA with and without indels. The other primer set was designed at the indel site, which does not detect <italic>Col8a2</italic> mRNA with indel but does detect normal <italic>Col8a2</italic> mRNA without indels. In C57BL/6J mice, the normal <italic>Col8a2</italic> mRNA (no indel) rates were 58.7 ± 11.4% (6.3 × 10<sup>6</sup> vg) and 56.1 ± 42.9% (25 × 10<sup>6</sup> vg), while in <italic>Col8a2<sup>Q455K</sup></italic> mice, the normal <italic>Col8a2</italic> mRNA (no indel) rates were 67.5 ± 19.0% (6.3 × 10<sup>6</sup> vg) and 35.4 ± 33.3% (25 × 10<sup>6</sup> vg) (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). Furthermore, Cas9 mRNA and gRNA were positively correlated (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). On the other hand, Cas9/gRNA and normal <italic>Col8a2</italic> mRNA rate were inversely correlated (<xref ref-type="fig" rid="fig6">Figure 6e and d</xref>). Thus, the anterior chamber injection of Ad-Cas9-Col8a2gRNA induces indels, directly correlated to the Cas9/gRNA expression in C57BL/6J and <italic>Col8a2<sup>Q455K</sup></italic> mice.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The indel rate was correlated to Cas9 and gRNA expression.</title><p>(<bold>a and b</bold>) Cas9 mRNA and gRNA expression in corneal endothelium 1 week following anterior chamber injection of Ad-Cas9-Col8a2gRNA. (<bold>c</bold>) The expression ratio of mouse Col8a2 mRNA without indels and total Col8a2 mRNA with/without indels were determined by real-time reverse transcription-PCR (RT-PCR). *p&lt;0.05 and **p&lt;0.01 by Student’s t-test. (<bold>d</bold>) gRNA and Cas9 mRNA expression are positively correlated. (<bold>e</bold>) Normal Col8a2 mRNA (no indel) rate and Cas9 mRNA are negatively correlated. (<bold>f</bold>) Normal Col8a2 mRNA (no indel) rate and gRNA expression are negatively correlated. The source data is Figure6_source data.xlsx.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Quantification by real-time PCR.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig6-v2.tif"/></fig></sec><sec id="s2-5"><title>Ad-Cas9-Col8a2gRNA rescues corneal endothelium architecture in <italic>Col8a2<sup>Q455K/Q455K</sup></italic> FECD mice</title><p>Next, we examined whether Ad-Cas9-Col8a2gRNA rescued corneal endothelium in the early-onset <italic>Col8a2<sup>Q455K/Q455K</sup></italic> FECD mouse model (<xref ref-type="bibr" rid="bib13">Jun et al., 2012</xref>). At 2 months of age, we performed a single intraocular injection of Ad-Cas9-Col8a2gRNA into one eye of each mouse. Non-injected contralateral eyes were used as controls. After the injection, the corneal endothelium was examined by in vivo corneal confocal microscopy (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Ad-Cas9-Col8a2gRNA-injected eyes showed slower reduction of corneal endothelium than the non-injected eyes (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). After 10 months (12-month-old), apparent differences between corneal endothelium of Ad-Cas9-Col8a2gRNA-injected and non-injected eyes were obvious (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). We found that intraocular injection of Ad-Cas9-Col8a2gRNA significantly rescued corneal endothelium in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice (<xref ref-type="fig" rid="fig7">Figure 7d</xref>). This was confirmed by Alizarin red staining (<xref ref-type="fig" rid="fig7">Figure 7e</xref>), which demonstrated a significantly higher corneal endothelium density in Ad-Cas9-Col8a2gRNA-injected corneas than in non-injected FECD eyes (<xref ref-type="fig" rid="fig7">Figure 7f</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Ad-Cas9-Col8a2gRNA intracameral injection rescues corneal endothelium loss in the early-onset Fuchs’ dystrophy mice (<italic>Col8a2</italic><sup>Q455K/Q455K</sup>) model.</title><p>(<bold>a</bold>) Representative in vivo corneal endothelium images using the Heidelberg Rostock microscope at 3 and 6 months post injection. Ad-Cas9-Col8a2gRNA was injected intracamerally into <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice at 2 months of age. Scale bar = 100 μm. (<bold>b</bold>) Time course change in corneal endothelial cell density of <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice, n = 5. Ad-Cas9-Col8a2gRNA slows loss of corneal endothelial cells compared to no-injection group. (<bold>c</bold>) Representative in vivo corneal endothelium image at 12 months of age. Age-matched C57BL/6J and non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice were used for comparison. Ad-Cas9-Col8a2gRNA qualitatively improved endothelial cell density. Scale bar = 100 μm. (<bold>d</bold>) Average corneal endothelium densities: C57BL/6J: 2134 ± 45 cells/mm<sup>2</sup>, non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 677 ± 110 cells/mm<sup>2</sup>, and Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 1141 ± 102 cells/mm<sup>2</sup>, n = 4. Error bars show standard deviation. (<bold>e</bold>) Representative corneal endothelium from each group stained with Alizarin red. Scale bar = 200 μm. (<bold>f</bold>) Average corneal endothelium densities calculated from Alizarin red-stained corneas: C57BL/6J: 2108 ± 134 cells/mm<sup>2</sup>, non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 696 ± 70 cells/mm<sup>2</sup>, and Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 1256 ± 135 cells/mm<sup>2</sup>, n = 4. Error bars show standard deviation. The source data is Figure7_source data.xlsx.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Corneal endothelial cell density in vivo and ex vivo.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig7-v2.tif"/></fig><p>Further detailed analysis of corneal endothelium indicated changes in cell density and morphology (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Analysis of paired corneas (injected and non-injected in the same mouse) showed significant improvements in corneal endothelial cell density by Ad-Cas9-Col8a2gRNA treatment in all four individual mice (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). <xref ref-type="fig" rid="fig8">Figure 8b</xref> shows the distribution of corneal endothelial cell area. The morphology of the corneal endothelium, as monitored by hexagonality, and coefficient of variation (COV) of its density were improved considerably (<xref ref-type="fig" rid="fig8">Figure 8c–d</xref>). In vivo corneal optical coherence tomography (OCT) demonstrated that Ad-Cas9-Col8a2gRNA decreased the formation of guttae-like structures compared to control (<xref ref-type="fig" rid="fig9">Figure 9a–b</xref>), which was confirmed by histology (<xref ref-type="fig" rid="fig9">Figure 9c–d</xref>). Thus, Ad-Cas9-Col8a2gRNA successfully ameliorated the loss of corneal endothelium and the morphologic phenotype in the early-onset FECD mouse model.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Ad-Cas9-Col8A2gRNA improves various characteristics of corneal endothelium in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice.</title><p>(<bold>a</bold>) Corneal endothelium density in each cornea was calculated using Alizarin red staining. A total of 50 different cell areas were measured in each cornea. Injected (Ad-Cas9-Col8a2gRNA) and non-injected corneas in the same mouse were compared by Student’s paired t-test. (<bold>b</bold>) Histogram of corneal endothelial cell area in Ad-Cas9-Col8A2gRNA-injected cornea and non-injected cornea quantitatively demonstrates left-shifting in cell size, that is, enhanced density, in the former. N = 200 in each group from four different corneas. (<bold>c</bold>) Hexagonality and (<bold>d</bold>) coefficient of variation (COV) of corneal endothelium were significantly improved by Ad-Cas9-Col8A2gRNA intracameral injection in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice. N = 200 from four different corneas in each group. The source data is Figure8_source data.xlsx.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>The area, hexagonality, and COV of corneal endothelial cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig8-v2.tif"/></fig><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Ad-Cas9-Col8A2gRNA reduced guttae-like structures on the corneal endothelium in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice.</title><p>(<bold>a</bold>) Corneal optical coherence tomography (OCT) revealed numerous guttae-like excrescences (arrows) in 1-year-old <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice, but far fewer in Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice. (<bold>b</bold>) Histogram showing the number of guttae-like structures in each group. Non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 5.2 ± 3.4 excrescences/image and Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>: 0.5 ± 0.73 excrescences/image. n = 16. P-value by Mann-Whitney U-test is &lt;0.001. (<bold>c<bold>,</bold> d</bold>) Periodic Acid-Schiff (PAS)-stained corneas from non-injected and Ad-Cas9-Col8a2gRNA-injected Col8A2<sup>Q455K/Q455K</sup> mice. The arrows indicate guttae-like structures (excrescences). The source data is Figure9_source data.xlsx.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Number of guttae-like structures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig9-v2.tif"/></fig></sec><sec id="s2-6"><title>Ad-Cas9-Col8a2gRNA rescues corneal endothelium function in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> FECD mice</title><p>Next, we examined whether Ad-Cas9-Col8a2gRNA could rescue corneal endothelial pump function of the <italic>Col8a2</italic><sup>Q455K/Q455K</sup> FECD mouse, which is essential for corneal clarity and optimal vision (<xref ref-type="bibr" rid="bib5">Bonanno, 2012</xref>). Surprisingly, <italic>Col8a2</italic><sup>Q455K/Q455K</sup> corneas did not develop edema or opacity even at 1 year of age despite reduced endothelial density (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>). We, therefore, developed a functional assay to deliberately induce corneal swelling and assess pump function by measuring the de-swelling rate. As direct application of a 0 mOsm/l solution was found to induce epithelial rather than stromal swelling (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2</xref>), we performed epithelial debridement to eliminate any confounding epithelial effects (<xref ref-type="fig" rid="fig10">Figure 10a</xref>). Application of an osmolar range of phosphate-buffered saline (PBS) solutions (<xref ref-type="fig" rid="fig10">Figure 10b</xref>) produced a range of swelling volumes, with 600–700 mOsm/l solution producing the maximal effect, with quadrupling of the stromal thickness (<xref ref-type="fig" rid="fig10">Figure 10b–c</xref>). Thus, the epithelial layer functions as a barrier to maintain stromal thickness, whereas hypertonic solutions seem to induce aqueous humor ingression into the cornea. Having optimized our model, we measured de-swelling rates following a 10-min application of 650 mOsm/l PBS. Successive corneal OCT images showed that the rate of de-swelling in non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> corneas was significantly delayed compared to C57BL/6J control corneas. In contrast, Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> corneas demonstrated de-swelling rates similar to C57BL/6J corneas (<xref ref-type="fig" rid="fig10">Figure 10d–e</xref>). Thus, Ad-Cas9-Col8a2gRNA rescued corneal endothelial function in FECD mice.</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Ad-Cas9-Col8a2gRNA rescued corneal endothelium pumping function in <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mouse.</title><p>(<bold>a</bold>) Stereomicroscopic images of scraped mouse cornea. (<bold>b</bold>) Corneal optical coherence tomography (OCT) images of pre-treatment, after scrape, and after treatment with 0 mOsm/l (water), 300, 600, 700, and 900 mOsm/l Dulbecco’s phosphate-buffered saline (DPBS) application followed by water again. (<bold>c</bold>) Changes in corneal thickness in response to variance in DPBS osmolality demonstrate that maximal swelling occurred at 600–700 mOsm/l DPBS. (<bold>d</bold>) Repeated measurements of central corneal thickness were taken using corneal OCT after application of 650 mOsm/l PBS. To prevent evaporation, 4 µl of silicone oil was applied at t = 0 (n = 6). <sup>#</sup>p&lt;0.001 by regression analysis. NS: not significant. (<bold>e</bold>) De-swelling of central corneal thickness was measured from 0 min to 5, 10, 20, 30, 40, and 50 min. Non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> corneas showed significantly delayed de-swelling compared to C57BL/6J corneas. In contrast, Ad-Cas9-Col8a2gRNA injection significantly improved corneal de-swelling rate similar to that of C57BL/6J controls (n = 6). *p&lt;0.05 by Student’s t-test. The source data is Figure10_source data.xlsx.</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>Time course change of corneal thickness.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig10-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig10-v2.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title><italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice (12 months old) did not show a significant difference in central corneal thickness.</title><p>Central corneal thickness was measured by corneal optical coherence tomography (OCT); p-value was calculated by analysis of variance (ANOVA). The source data is Figure10-figure supplement1_source data.xlsx.</p><p><supplementary-material id="fig10s1sdata1"><label>Figure 10—figure supplement 1—source data 1.</label><caption><title>Central corneal thickness.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig10-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig10-figsupp1-v2.tif"/></fig><fig id="fig10s2" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 2.</label><caption><title>Water applied to the corneal surface expands the thickness of corneal epithelium rather than the stroma.</title><p>(<bold>a</bold>) Representative corneal optical coherence tomography (OCT) images before and after water was applied for 10 min. (<bold>b</bold>) The average thickness of total, upper (epithelium), and lower (stroma) corneal surface before and after water application for 10 min. n = 5. Error bars show standard deviation; p-value was calculated by Student’s t-test. The source data is Figure10-figure supplement2_source data.xlsx.</p><p><supplementary-material id="fig10s2sdata1"><label>Figure 10—figure supplement 2—source data 1.</label><caption><title>Thickness of epithelium and stroma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55637-fig10-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig10-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Potential off-target effects of gRNA targeting the human <italic>COL8A2</italic> start codon</title><p>For potential therapeutic application of CRISPR/Cas9, we evaluated the off-target activity of humanized gRNA by a modified digenome analysis (<xref ref-type="bibr" rid="bib14">Kim et al., 2015</xref>). Briefly, digenome analysis consists of (1) in vitro digestion of purified gDNA with SpCas9 and gRNA; (2) deep sequencing of the digested gDNA; and (3) alignment of sequence reads at the digested sites. Consequently, digested sites other than the target site are considered potential off-target sites. In fact, we found that the readings at the target site (human <italic>COL8A2</italic> start codon) were aligned but not without gRNA (<xref ref-type="fig" rid="fig11">Figure 11a–b</xref>). After careful observation, a gap was often found at the target site (<xref ref-type="fig" rid="fig11">Figure 11c</xref>). Since off-target analysis without considering such a gap would underestimate off-target events, we included a ± 1 gap in our modified digenome analysis. <xref ref-type="fig" rid="fig11">Figure 11d</xref> shows the digenome score alignments of control gDNA (no gRNA) and treated gDNA (HuCol8a2gRNA). From this, candidate sites were selected, for which the score was &gt;60. We identified eight different sequences in 13 different locations that had homology to HuCol8a2gRNA and were associated with a PAM sequence (<xref ref-type="table" rid="table4">Table 4</xref>). The majority of these sequences were non-coding sites, and the remaining sites (two of which were anti-sense sites and two of which were intronic sites) (<italic>SRGAP2-AS1, SV2C, KAT6B, LMO7-AS1, ACAN</italic>) have no known corneal function. <xref ref-type="table" rid="table5">Table 5</xref> shows 8 of 21 candidates that had neither homology to HuCol8a2gRNA nor PAM sequence. <xref ref-type="table" rid="table6">Table 6</xref> shows four sequences in control gDNA.</p><fig-group><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Modified digenome analysis for potential off-targets.</title><p>(<bold>a, b</bold>) Mapping of reads to human <italic>COL8A2</italic> target site from HuCol8a2gRNA-treated genomic DNA (gDNA) and control gDNA. (<bold>c</bold>) A gap was observed in in vitro digestion of genomic DNA. (<bold>d</bold>) Modified digenome score alignment (0–1.0) of control gDNA (no gRNA) and HuGol8a2gRNA-treated gDNA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig11-v2.tif"/></fig><fig id="fig11s1" position="float" specific-use="child-fig"><label>Figure 11—figure supplement 1.</label><caption><title>In vitro digestion by Cas9/HuCol8a2gRNA.</title><p>(<bold>a</bold>) Plasmid-based Cas9/HuCol8a2gRNA induced (insertions/deletions) indels in AD293 cells. Arrow indicates an indel band. (<bold>b</bold>) Gel electrophoresis image of in vitro transcription of HuCol8a2gRNA. (<bold>c</bold>) PCR confirmed in vitro digestion of purified AD293 genomic DNA by Cas9/HuCol8a2gRNA. PCR primers were designed to target the digestion site.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55637-fig11-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>HuCol8a2gRNA off-target sites with homology.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th valign="bottom">Chr</th><th valign="bottom">Gap</th><th valign="bottom">Start</th><th valign="bottom">Gene</th><th valign="bottom">Plus</th><th valign="bottom">Depth</th><th valign="bottom">Perc</th><th valign="bottom">Minus</th><th valign="bottom">Depth</th><th valign="bottom">Perc</th><th valign="bottom">Total</th><th valign="bottom">Sequence with PAM*</th><th valign="bottom">Identity (% including PAM)</th></tr></thead><tbody><tr><td valign="bottom">1</td><td valign="bottom">1</td><td valign="bottom">0</td><td valign="bottom">36100241</td><td rowspan="3" valign="bottom"><italic>COL8A2,</italic> coding (target site)</td><td valign="bottom">13</td><td valign="bottom">13</td><td valign="bottom">100</td><td valign="bottom">5</td><td valign="bottom">6</td><td valign="bottom">83.33</td><td valign="bottom">94.74</td><td valign="bottom">CGTCCACGGACGCCATGCTGGG</td><td valign="bottom">100</td></tr><tr><td valign="bottom"/><td valign="bottom">1</td><td valign="bottom">1</td><td valign="bottom">36100241</td><td valign="bottom">13</td><td valign="bottom">13</td><td valign="bottom">100</td><td valign="bottom">9</td><td valign="bottom">15</td><td valign="bottom">60</td><td valign="bottom">78.57</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom"/><td valign="bottom">1</td><td valign="bottom">1</td><td valign="bottom">36100241</td><td valign="bottom">11</td><td valign="bottom">11</td><td valign="bottom">100</td><td valign="bottom">7</td><td valign="bottom">11</td><td valign="bottom">63.64</td><td valign="bottom">81.82</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">2</td><td valign="bottom">1</td><td valign="bottom">-1</td><td valign="bottom">143388988</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">21</td><td valign="bottom">30</td><td valign="bottom">70</td><td valign="bottom">26</td><td valign="bottom">29</td><td valign="bottom">89.66</td><td valign="bottom">79.66</td><td valign="bottom">CGTCCATGGACCCCAAGCTAGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">1</td><td valign="bottom">0</td><td valign="bottom">143388989</td><td valign="bottom">29</td><td valign="bottom">59</td><td valign="bottom">49.15</td><td valign="bottom">26</td><td valign="bottom">29</td><td valign="bottom">89.66</td><td valign="bottom">62.5</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">3</td><td valign="bottom">1</td><td valign="bottom">-1</td><td valign="bottom">144214582</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">21</td><td valign="bottom">30</td><td valign="bottom">70</td><td valign="bottom">26</td><td valign="bottom">31</td><td valign="bottom">83.87</td><td valign="bottom">77.05</td><td valign="bottom">CGTCCATGGACCCCAAGCTAGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">1</td><td valign="bottom">0</td><td valign="bottom">144214583</td><td valign="bottom">29</td><td valign="bottom">59</td><td valign="bottom">49.15</td><td valign="bottom">26</td><td valign="bottom">31</td><td valign="bottom">83.87</td><td valign="bottom">61.11</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">4</td><td valign="bottom">1</td><td valign="bottom">-1</td><td valign="bottom">144751794</td><td rowspan="2" valign="bottom">SRGAP2-AS1</td><td valign="bottom">26</td><td valign="bottom">31</td><td valign="bottom">83.87</td><td valign="bottom">20</td><td valign="bottom">29</td><td valign="bottom">68.97</td><td valign="bottom">76.67</td><td valign="bottom">CGTCCATGGACCCCAAGCTAGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">1</td><td valign="bottom">0</td><td valign="bottom">144751794</td><td valign="bottom">26</td><td valign="bottom">31</td><td valign="bottom">83.87</td><td valign="bottom">29</td><td valign="bottom">58</td><td valign="bottom">50</td><td valign="bottom">61.8</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">5</td><td valign="bottom">2</td><td valign="bottom">-1</td><td valign="bottom">89549893</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">21</td><td valign="bottom">30</td><td valign="bottom">70</td><td valign="bottom">17</td><td valign="bottom">20</td><td valign="bottom">85</td><td valign="bottom">76</td><td valign="bottom">CGTCCATGGACCCCAAGCTAGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">2</td><td valign="bottom">0</td><td valign="bottom">89549894</td><td valign="bottom">29</td><td valign="bottom">59</td><td valign="bottom">49.15</td><td valign="bottom">17</td><td valign="bottom">20</td><td valign="bottom">85</td><td valign="bottom">58.23</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">6</td><td valign="bottom">2</td><td valign="bottom">-1</td><td valign="bottom">91624245</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">21</td><td valign="bottom">30</td><td valign="bottom">70</td><td valign="bottom">26</td><td valign="bottom">29</td><td valign="bottom">89.66</td><td valign="bottom">79.66</td><td valign="bottom">CGTCCATGGACCCCAAGCTAGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">2</td><td valign="bottom">0</td><td valign="bottom">91624246</td><td valign="bottom">29</td><td valign="bottom">59</td><td valign="bottom">49.15</td><td valign="bottom">26</td><td valign="bottom">29</td><td valign="bottom">89.66</td><td valign="bottom">62.5</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">7</td><td valign="bottom">4</td><td valign="bottom">-1</td><td valign="bottom">3707175</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">7</td><td valign="bottom">8</td><td valign="bottom">87.5</td><td valign="bottom">10</td><td valign="bottom">10</td><td valign="bottom">100</td><td valign="bottom">94.44</td><td>TGCCCACGGGCACCATGTTGGG</td><td valign="bottom">77.3</td></tr><tr><td valign="bottom"/><td valign="bottom">4</td><td valign="bottom">-1</td><td valign="bottom">3707175</td><td valign="bottom">7</td><td valign="bottom">8</td><td valign="bottom">87.5</td><td valign="bottom">9</td><td valign="bottom">9</td><td valign="bottom">100</td><td valign="bottom">94.12</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">8</td><td valign="bottom">4</td><td valign="bottom">-1</td><td valign="bottom">4185990</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">15</td><td valign="bottom">21</td><td valign="bottom">71.43</td><td valign="bottom">19</td><td valign="bottom">28</td><td valign="bottom">67.86</td><td valign="bottom">69.39</td><td>AGTCCATGGACCACAAGCTAGG</td><td valign="bottom">72.7</td></tr><tr><td valign="bottom"/><td valign="bottom">4</td><td valign="bottom">0</td><td valign="bottom">4185990</td><td valign="bottom">15</td><td valign="bottom">21</td><td valign="bottom">71.43</td><td valign="bottom">26</td><td valign="bottom">54</td><td valign="bottom">48.15</td><td valign="bottom">54.67</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">9</td><td valign="bottom">5</td><td valign="bottom">-1</td><td valign="bottom">76221510</td><td rowspan="2" valign="bottom"><italic>SV2C,</italic> intron</td><td valign="bottom">9</td><td valign="bottom">11</td><td valign="bottom">81.82</td><td valign="bottom">10</td><td valign="bottom">17</td><td valign="bottom">58.82</td><td valign="bottom">67.86</td><td>TGTCCAC-AACGTCATGCTTGG</td><td valign="bottom">72.7</td></tr><tr><td valign="bottom"/><td valign="bottom">5</td><td valign="bottom">-1</td><td valign="bottom">76221510</td><td valign="bottom">9</td><td valign="bottom">11</td><td valign="bottom">81.82</td><td valign="bottom">7</td><td valign="bottom">14</td><td valign="bottom">50</td><td valign="bottom">64</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">10</td><td valign="bottom">10</td><td valign="bottom">-1</td><td valign="bottom">74854844</td><td rowspan="2" valign="bottom"><italic>KAT6B,</italic> intron</td><td valign="bottom">12</td><td valign="bottom">20</td><td valign="bottom">60</td><td valign="bottom">21</td><td valign="bottom">21</td><td valign="bottom">100</td><td valign="bottom">80.49</td><td>CGTACACAGAAACCATGCTGGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">10</td><td valign="bottom">-1</td><td valign="bottom">74854844</td><td valign="bottom">12</td><td valign="bottom">20</td><td valign="bottom">60</td><td valign="bottom">19</td><td valign="bottom">19</td><td valign="bottom">100</td><td valign="bottom">79.49</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">11</td><td valign="bottom">10</td><td valign="bottom">-1</td><td valign="bottom">130741051</td><td rowspan="2" valign="bottom">Intergenic</td><td valign="bottom">7</td><td valign="bottom">10</td><td valign="bottom">70</td><td valign="bottom">10</td><td valign="bottom">16</td><td valign="bottom">62.5</td><td valign="bottom">65.38</td><td>AGTCCA-GGAGGCCATGCTTGG</td><td valign="bottom">81.8</td></tr><tr><td valign="bottom"/><td valign="bottom">10</td><td valign="bottom">-1</td><td valign="bottom">130741051</td><td valign="bottom">7</td><td valign="bottom">10</td><td valign="bottom">70</td><td valign="bottom">10</td><td valign="bottom">16</td><td valign="bottom">62.5</td><td valign="bottom">65.38</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">12</td><td valign="bottom">13</td><td valign="bottom">-1</td><td valign="bottom">75612825</td><td rowspan="2" valign="bottom">LMO7-AS1</td><td valign="bottom">8</td><td valign="bottom">14</td><td valign="bottom">57.14</td><td valign="bottom">13</td><td valign="bottom">17</td><td valign="bottom">76.47</td><td valign="bottom">67.74</td><td valign="bottom">GGTCCAC-GCCGCCATGCCCGG</td><td valign="bottom">77.3</td></tr><tr><td valign="bottom"/><td valign="bottom">13</td><td valign="bottom">-1</td><td valign="bottom">75612825</td><td valign="bottom">8</td><td valign="bottom">14</td><td valign="bottom">57.14</td><td valign="bottom">13</td><td valign="bottom">16</td><td valign="bottom">81.25</td><td valign="bottom">70</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">13</td><td valign="bottom">15</td><td valign="bottom">1</td><td valign="bottom">88847941</td><td rowspan="2" valign="bottom"><italic>ACAN,</italic> coding</td><td valign="bottom">16</td><td valign="bottom">16</td><td valign="bottom">100</td><td valign="bottom">18</td><td valign="bottom">21</td><td valign="bottom">85.71</td><td valign="bottom">91.89</td><td>AGCCCCCGGACCCCATGCGTGG</td><td valign="bottom">77.3</td></tr><tr><td valign="bottom"/><td valign="bottom">15</td><td valign="bottom">1</td><td valign="bottom">88847941</td><td valign="bottom">16</td><td valign="bottom">16</td><td valign="bottom">100</td><td valign="bottom">17</td><td valign="bottom">20</td><td valign="bottom">85</td><td valign="bottom">91.67</td><td valign="bottom"/><td valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>*Red characters indicate mismatched DNA residues.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>HuCol8a2gRNA off-target sites without homology.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Location</th><th valign="bottom">Chr</th><th valign="bottom">Gap</th><th valign="bottom">Start</th><th valign="bottom">Plus</th><th valign="bottom">Depth</th><th valign="bottom">Perc</th><th valign="bottom">Minus</th><th valign="bottom">Depth2</th><th valign="bottom">Perc2</th><th valign="bottom">Total</th><th valign="bottom">Sequence (50 bp around the detection site)</th></tr></thead><tbody><tr><td valign="bottom">1</td><td valign="bottom">3</td><td valign="bottom">1</td><td valign="bottom">189206630</td><td valign="bottom">5</td><td valign="bottom">10</td><td valign="bottom">50</td><td valign="bottom">6</td><td valign="bottom">9</td><td valign="bottom">66.67</td><td valign="bottom">57.89</td><td align="center" rowspan="2" valign="top"><named-content content-type="sequence">gaacctcccacctcagcctaccgagtagctgagactatgggcacattccg</named-content></td></tr><tr><td valign="bottom"/><td valign="bottom">3</td><td valign="bottom">1</td><td valign="bottom">189206630</td><td valign="bottom">5</td><td valign="bottom">9</td><td valign="bottom">55.56</td><td valign="bottom">5</td><td valign="bottom">7</td><td valign="bottom">71.43</td><td valign="bottom">62.5</td></tr><tr><td valign="top">2</td><td valign="top">4</td><td valign="top">0</td><td valign="top">83023938</td><td valign="top">5</td><td valign="top">7</td><td valign="top">71.43</td><td valign="top">6</td><td valign="top">11</td><td valign="top">54.55</td><td valign="top">61.11</td><td valign="top"><named-content content-type="sequence">acacatggacacagggagggggacatcactgtgtgatgtggggggcaagg</named-content></td></tr><tr><td valign="top">3</td><td valign="top">8</td><td valign="top">1</td><td valign="top">1351347</td><td valign="top">6</td><td valign="top">11</td><td valign="top">54.55</td><td valign="top">12</td><td valign="top">16</td><td valign="top">75</td><td valign="top">66.67</td><td valign="top"><named-content content-type="sequence">ggccgtgcgggtcctgagtgtggaacggccgtgcgggtcctgactgtgtg</named-content></td></tr><tr><td valign="top">4</td><td valign="top">8</td><td valign="top">0</td><td valign="top">143167239</td><td valign="top">15</td><td valign="top">26</td><td valign="top">57.69</td><td valign="top">11</td><td valign="top">13</td><td valign="top">84.62</td><td valign="top">66.67</td><td valign="top"><named-content content-type="sequence">ggaagtggagaaggggaaggaaggtcgtctagggaggaagtggagagggg</named-content></td></tr><tr><td valign="top">5</td><td valign="top">9</td><td valign="top">1</td><td valign="top">64082996</td><td valign="top">6</td><td valign="top">11</td><td valign="top">54.55</td><td valign="top">5</td><td valign="top">7</td><td valign="top">71.43</td><td valign="top">61.11</td><td valign="top"><named-content content-type="sequence">tatatatatatatatatatatatatatatatatatatatatatatatata</named-content></td></tr><tr><td valign="top">6</td><td valign="top">10</td><td valign="top">1</td><td valign="top">3085303</td><td valign="top">15</td><td valign="top">17</td><td valign="top">88.24</td><td valign="top">7</td><td valign="top">13</td><td valign="top">53.85</td><td valign="top">73.33</td><td valign="top"><named-content content-type="sequence">cccccactccactctccagcacagtcccccactccactctccagcacagt</named-content></td></tr><tr><td valign="top">7</td><td valign="top">16</td><td valign="top">-1</td><td valign="top">19382526</td><td valign="top">5</td><td valign="top">8</td><td valign="top">62.5</td><td valign="top">5</td><td valign="top">8</td><td valign="top">62.5</td><td valign="top">62.5</td><td valign="top"><named-content content-type="sequence">agttctcatctggaatttctataatagacccagagtcaacagccaggttc</named-content></td></tr><tr><td valign="top">8</td><td valign="top">16</td><td valign="top">-1</td><td valign="top">34625947</td><td valign="top">46</td><td valign="top">57</td><td valign="top">80.7</td><td valign="top">8</td><td valign="top">26</td><td valign="top">30.77</td><td valign="top">65.06</td><td valign="top"><named-content content-type="sequence">caaagctatccaaatatccacttgtagattatattcgagtgcattcgatg</named-content></td></tr></tbody></table></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Detected sites with digenome scores &gt;60 in the control genomic DNA.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Location</th><th valign="bottom">Chr</th><th valign="bottom">Gap</th><th valign="bottom">Start</th><th valign="bottom">Plus</th><th valign="bottom">Depth</th><th valign="bottom">Perc</th><th valign="bottom">Minus</th><th valign="bottom">Depth2</th><th valign="bottom">Perc2</th><th valign="bottom">Total</th><th valign="bottom">Sequence (50 bp around the detection site)</th></tr></thead><tbody><tr><td valign="top">1</td><td valign="top">2</td><td valign="top">1</td><td valign="top">112180048</td><td valign="top">5</td><td valign="top">10</td><td valign="top">50</td><td valign="top">5</td><td valign="top">6</td><td valign="top">83.33</td><td valign="top">62.5</td><td valign="top"><named-content content-type="sequence">aaaagaaagtatcaaaggagtaaacagacaacctacagaatgggagaaaa</named-content></td></tr><tr><td valign="top">2</td><td valign="top">8</td><td valign="top">0</td><td valign="top">58814608</td><td valign="top">6</td><td valign="top">9</td><td valign="top">66.67</td><td valign="top">5</td><td valign="top">9</td><td valign="top">55.56</td><td valign="top">61.11</td><td valign="top"><named-content content-type="sequence">atagttttaggatttcaggatgccttctgttcagtttagtttatattgtt</named-content></td></tr><tr><td valign="top">3</td><td valign="top">12</td><td valign="top">1</td><td valign="top">74918031</td><td valign="top">5</td><td valign="top">7</td><td valign="top">71.43</td><td valign="top">5</td><td valign="top">8</td><td valign="top">62.5</td><td valign="top">66.67</td><td valign="top"><named-content content-type="sequence">tacctagaaagcaagcagaatactcttagccaagaaaacaatatgtactc</named-content></td></tr><tr><td valign="top">4</td><td valign="top">18</td><td valign="top">-1</td><td valign="top">49878347</td><td valign="top">5</td><td valign="top">10</td><td valign="top">50</td><td valign="top">6</td><td valign="top">8</td><td valign="top">75</td><td valign="top">61.11</td><td valign="top"><named-content content-type="sequence">ttaaaaatacttttttttttcctgcatctgatttggctgtcagtgtgaaa</named-content></td></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we demonstrated that intraocular injection of a single adenoviral vector achieved efficient and restricted delivery of CRISPR/Cas9 to adult post-mitotic corneal endothelium, leading to in vivo knockdown of mutant <italic>Col8a2</italic> with long-term preservation of corneal endothelial density, structure, and function in the early-onset Fuchs’ dystrophy mouse model.</p><p>We found that most of the insertions were single insertions of adenine, creating a cryptic start codon without frame shift (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). As mentioned above, this would disrupt the Kozak sequence. Taken together, our results indicate that disruption of the Kozak sequence effectively reduces protein expression without complications such as non-functional or frame-shifted protein production. Hence, Kozak sequence disruption by CRISPR/Cas9 targeting may provide a viable option for gene knockdown.</p><p>In this study, we performed the modified digenome method to determine potential off-target regions. Interestingly, we found a gap at the target site (<xref ref-type="fig" rid="fig11">Figure 11c</xref>). This gap may have been generated during sample preparation, due to causes such as Covaris shearing, polishing of overhanging DNA, and adenylation at 3’-end for ligation or fluctuation of Cas9/gRNA recognition to gDNA. We identified 13 potential off-target sites with homology, the majority of which were in non-coding sequences and other regions in genes of uncertain function. We found one potential coding exonic off-target sequence in the <italic>ACAN</italic> gene. ACAN (also referred to as aggrecan core protein) is a major component of extracellular matrix of cartilaginous tissues. Although several cartilage-bone-related diseases are caused by mutations of <italic>ACAN</italic> coding region, its expression was not observed in previously published RNAseq data of human corneal endothelium (<xref ref-type="bibr" rid="bib33">Wieben et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Wieben et al., 2019</xref>). Therefore, it is unlikely that this off-target indel would affect corneal function. We found off-target sequences in the intron of two genes, <italic>SV2C (Synaptic vesicle glycoprotein 2C)</italic> and <italic>KAT6B. SV2C</italic> is involved in synaptic function throughout the brain (<xref ref-type="bibr" rid="bib8">Dunn et al., 2017</xref>), but it is rarely expressed in human corneal endothelium (<xref ref-type="bibr" rid="bib33">Wieben et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Wieben et al., 2019</xref>). <italic>KAT6B</italic> is a histone acetyltransferase that may be involved in both positive and negative regulation of transcription. Several developmental disorders are caused by distinct mutations of <italic>KAT6B</italic> (<xref ref-type="bibr" rid="bib6">Campeau et al., 2012</xref>), and acute myeloid leukemia may be caused by a chromosomal aberration involving <italic>KAT6B</italic> gene (<xref ref-type="bibr" rid="bib26">Panagopoulos et al., 2001</xref>). Therefore, <italic>KAT6B</italic> gene should be considered a gene at risk with our Crispr/Cas9 treatment. In most cases, intronic mutations causing human diseases are located within 100 bp from intron–exon boundary, as most diseases associated with intronic mutation create a pseudo-exon that disrupts splicing. The observed <italic>KAT6B</italic> off-target site is located over 11,000 bp from the exon–intron boundary. Hence, the off-target mutation in <italic>KAT6B</italic> is unlikely to cause corneal dysfunction. Two additional off-target candidates were found in the intron of non-coding RNAs, <italic>SRGAP2-AS1</italic> and <italic>LMO7-AS1</italic>. Non-coding RNAs are sometimes known to have various functions in gene regulation, but the functions of <italic>SRGAP2-AS1</italic> and <italic>LMO7-AS1</italic> are unknown. All other off-target candidates are located in intergenic regions. Since some intergenic regions contain gene enhancer elements, mutations could theoretically contribute to disease risk (<xref ref-type="bibr" rid="bib3">Bartonicek et al., 2017</xref>). Compared with exonic or intronic mutations, the risk of intergenic mutations inducing deleterious effects would be low. Thus, we identified off-target candidates of our CRISPR/Cas9 treatment that are expected to not cause corneal dysfunction. However, testing in large animals such as non-human primates should be performed prior to any clinical testing of in vivo CRISPR/cas9 treatment for humans.</p><p>Eight potential off-target sites without homology or PAM sequence were found, but we speculate these are likely random errors since the non-gRNA control also showed four potential off-target sites.</p><p>Previous papers have achieved in vivo editing in post-mitotic neurons using dual adeno-associated virus (AAV) to co-infect cells with Cas9 machinery (<xref ref-type="bibr" rid="bib25">Nishiyama et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Yu et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Zhu et al., 2017</xref>). Although AAV has the advantages of low immunogenicity and toxicity, the low efficiency of HR by dual AAV delivery (10–12%) (<xref ref-type="bibr" rid="bib25">Nishiyama et al., 2017</xref>) is unrealistic as a treatment approach, and the complexity of two vectors makes targeting efficacy assessment and clinical development challenging. Moreover, the long-term expression of AAV-based CRISPR/Cas9 may ultimately prove undesirable for a post-mitotic cell, since the potential for off-target gene editing will continue for the life of the AAV. In contrast, the high infectivity and short duration of adenoviral expression would enable structural and functional rescue by Ad-Cas9-Col8a2gRNA at a titer below adenoviral cytotoxicity, without risk of further (<italic>mis</italic>) editing events.</p><p>In conclusion, we succeeded in <italic>Col8a2</italic> gene knockdown in corneal endothelium in vivo using an adenovirus-mediated SpCas9 and gRNA delivery, resulting in a functionally relevant rescue of corneal endothelium in the early-onset FECD mouse model. Our strategy can be applicable to other genes and useful in experiments. While a previous study (<xref ref-type="bibr" rid="bib35">Yu et al., 2017</xref>) has shown prevention of neurodegeneration with a similar strategy, this is the first demonstration of functional rescue with Cas9-mediated gene knockdown using start codon disruption. Future studies will explore the impact of this approach on endothelial and inflammatory gene expression using RNA-Seq and whether we can suppress activation of the unfolded protein response in endothelial cells. In addition, prior to clinical development, gene therapy approaches will require optimization of gRNA and Cas9, understanding long-term effects, and refinement of the delivery strategy. Still, these results strongly suggest that our strategy can treat or at least prolong corneal endothelial life in early-onset Fuchs’ dystrophy, potentially eliminating the need for transplantation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Strain, strain background (<italic>Mus musculus</italic>, C57BL/6J)</td><td>C57BL/6J</td><td valign="bottom">Jackson laboratories</td><td valign="bottom">Stock # 000664 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>, 129S6/SvEvTac and C57BL/6J)</td><td><italic>Col8a2<sup>Q455K</sup></italic></td><td valign="bottom">Johns Hopkins Medical Institutions</td><td valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22002996">22002996</ext-link> <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5305276">MGI:5305276</ext-link></td><td/></tr><tr><td>Antibody</td><td>a-COL8A2, rabbit polyclonal,</td><td valign="bottom">Thermo Fisher Scientific</td><td valign="bottom">Cat# PA5-35077 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2552387">AB_2552387</ext-link></td><td>(5 μg/ml)</td></tr><tr><td>Antibody</td><td>Isotype, rabbit polyclonal</td><td valign="bottom">Thermo Fisher Scientific</td><td valign="bottom">Cat# 02–6102 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2532938">AB_2532938</ext-link></td><td>(5 μg/ml)</td></tr><tr><td>Antibody</td><td>a-ZO1, mouse monoclonal</td><td valign="bottom">Thermo Fisher Scientific</td><td valign="bottom">Cat# 339188 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2532187">AB_2532187</ext-link></td><td>(2.5 μg/ml)</td></tr><tr><td>Antibody</td><td>a-TNFa, rat monoclonal</td><td valign="bottom">BioLegend</td><td valign="bottom">Cat# 506301, clone: MP6-XT22 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_315422">AB_315422</ext-link></td><td>(5 μg/ml)</td></tr><tr><td>Antibody</td><td>a-IFNg, rat monoclonal</td><td valign="bottom">BioLegend</td><td valign="bottom">Cat# 505801, clone: XMG1.2 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_315395">AB_315395</ext-link></td><td>(5 μg/ml)</td></tr><tr><td>Antibody</td><td>Isotype, rat monoclonal</td><td valign="bottom">BioLegend</td><td valign="bottom">Cat# 400401, clone RTK2071 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_326507">AB_326507</ext-link></td><td>(5 μg/ml)</td></tr><tr><td>Antibody</td><td>Secondary to rat IgG, conjugated with AlexaFluor647, goat polyclonal</td><td valign="bottom">Thermo Fisher Scientific</td><td valign="bottom">Cat# A-21247 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_141778">AB_141778</ext-link></td><td>(2 μg/ml)</td></tr><tr><td>Cell line (human)</td><td>AD-293</td><td valign="bottom">Agilent Technologies</td><td>Cat# 240085</td><td/></tr><tr><td>Cell line (mouse)</td><td>NIH3T3</td><td>ATCC</td><td>Cat# CRL-1658 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0594">CVCL_0594</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>px330</td><td>Addgene</td><td>Cat# 42230 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_42230">Addgene_42230</ext-link></td><td>Plasmid</td></tr><tr><td>Recombinant DNA reagent</td><td>pShuttle</td><td>Addgene</td><td>Cat# 16402 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_16402">Addgene_16402</ext-link></td><td>Plasmid</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="bottom">BJ5183-AD-1</td><td valign="bottom">Agilent Technologies</td><td>Cat# 200157</td><td>Competent cells</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="bottom">XL10-Gold</td><td valign="bottom">Agilent Technologies</td><td>Cat# 200314</td><td>Competent cells</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="bottom">DH5a</td><td>NEB</td><td>Cat# C2987H</td><td>Competent cells</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">MsCol8a2_intron2F</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">cggtggtaggtggtaattgg</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">MsCol8a2_intron3R</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">tgtggtctggagtgtctgga</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">gRNAcloneF_EcoRV</td><td valign="bottom">This paper</td><td valign="bottom">PCR primer</td><td valign="bottom">TAGATATCgagggcctatttcccatgattc</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">gRNAcloneR_XbaI</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">TATCTAGAagccatttgtctgcagaattggc</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Forward PCR primer for DNAseq</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">TTCTTCTTCTCCCTGCAGCC</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Reverse PCR primer for DNAseq</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">GCACATACTTTACCGGGGCA</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">HuCol8a2_F</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">tgatcttttggtgaccccgg</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">HuCol8a2_R</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">GGATGTACTTCACTGGGGCA</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Forward PCR primer for gRNA template of in vitro transcription</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">TAATACGACTCACTATAGCGTCCACGGACGCCATG</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Reverse PCR primer for gRNA template of in vitro transcription</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">AAAAGCACCGACTCGGTGCCA</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Cas9_Forward</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">CCGAAGAGGTCGTGAAGAAG</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Cas9_Reverse</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">GCCTTATCCAGTTCGCTCAG</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">gRNA_Forward</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">AGACGCCATGCGTTTTAGAG</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">gRNA_Reverse</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">CGGTGCCACTTTTTCAAGTT</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse GAPDH_Forward</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">AACTTTGGCATTGTGGAAGGGCTC</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse GAPDH_Reverse</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">ACCAGTGGATGCAGGGATGATGTT</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse Col8a2_Forward1 at Indel site</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">CCACCTACACGTACGACGAA</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse Col8a2_Reverse1</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">ACTCGGTGGAGTAGAGACCA</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse Col8a2_Forward2</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">CCATCCACAGACGCCATG</td></tr><tr><td>Sequence-based reagent</td><td valign="bottom">Mouse Col8a2_Reverse2</td><td valign="bottom">This paper</td><td>PCR primer</td><td valign="bottom">GGGCTGCACATACTTTACCG</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6J mice, 8–12 weeks old, were purchased from The Jackson Laboratory (Bar Harbor, ME) and used in this study. The <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mouse has been previously described (<xref ref-type="bibr" rid="bib20">Meng et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Jun et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Matthaei et al., 2012</xref>). All animals were treated according to the Association for Research in Vision and Ophthalmology(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.</p></sec><sec id="s4-2"><title>Plasmid construction</title><p>px330 plasmid encoding humanized <italic>Streptococcus pyogenes</italic> Cas9 was obtained from Addgene (Cambridge, MA). The design of gRNA and cloning were performed following published methods (<xref ref-type="bibr" rid="bib7">Cong et al., 2013</xref>). Three separate gRNAs were designed to target sequences containing a trinucleotide PAM sequence (in italics):</p><p>Col8a2-gRNA1: <named-content content-type="sequence">CCCATCCACAGACGCCATGC<italic>AGG</italic></named-content>;</p><p>Col8a2-gRNA2: <named-content content-type="sequence">GGGTGCAGCGGGCTATGCCC<italic>CGG</italic></named-content>;</p><p>Col8a2-gRNA3: <named-content content-type="sequence">CCGCCTTTCCGAGAGGGCAA<italic>AGG</italic></named-content>.</p></sec><sec id="s4-3"><title>Cell lines</title><p>AD-293 cells were obtained from Agilent technology (Santa Clara, CA) in 2014. AD-293 cells are HEK-293-derived cells for adenovirus production. We provided genome sequences of our AD-293 cells in digenome experiments and were able to obtain adequate titers of adenovirus, substantiating the HEK-293 origin of this cell line. NIH3T3 cells were obtained from ATCC (Manassas, VA), which conducted the cell authentication. Both Agilent and ATCC tested for mycoplasma with negative tests. We did not use any of these cells after passage 10.</p></sec><sec id="s4-4"><title>Cell culture, plasmid transfection, and indel detection</title><p>Mouse NIH3T3 cells were maintained in 10% bovine calf serum/Dulbecco’s Modified Eagle’s medium (DMEM) following manufacturer’s instructions. 2 μg of plasmid was transfected by nucleofection (Lonza, Allendale, NJ). After 2 days, gDNA was purified using QIAamp DNA Mini Kit (Qiagen, Valencia, CA). 10 ng of gDNA was PCR amplified with the following primer set: MsCol8a2_intron2F: <named-content content-type="sequence">cggtggtaggtggtaattgg</named-content> and MsCol8a2_intron3R: <named-content content-type="sequence">tgtggtctggagtgtctgga</named-content>. The PCR product (560 bp) was purified with a Qiagen PCR purification kit and subsequently digested by CviAII restriction enzyme (NEB, Ipswich, MA) or Hin1II (Thermo Fisher Scientific, Waltham, MA) following the manufacturer’s protocols. We initially used CviAII before switching to Hin1ll due to low stability of CviAII (both enzymes cut CATG). Digested products were run on a 1% agarose electrophoresis gel. Uncut bands (~420 bp) were purified and cloned with CloneJET PCR Cloning kit (Thermo Fisher Scientific). After transformation to DH5α (NEB), individual colonies were cultured in lysogeny broth (LB) medium with ampicillin, purified via miniprep, and sent to the University of Utah DNA core facility for Sanger sequencing.</p></sec><sec id="s4-5"><title>Adenovirus production</title><p>Adenovirus production was carried out following previously published methods (<xref ref-type="bibr" rid="bib17">Luo et al., 2007</xref>). All restriction enzymes described here were purchased from NEB. Empty Shuttle vector (pShuttle, #16402) was obtained from Addgene. Col8a2-gRNA1 with U6 promoter and terminator was amplified from pCas9-Col8A2gRNA by PCR using the following primers: gRNAcloneF_EcoRV: <named-content content-type="sequence">TAGATATCgagggcctatttcccatgattc</named-content> and gRNAcloneR_XbaI: <named-content content-type="sequence">TATCTAGAagccatttgtctgcagaattggc</named-content>. PCR product was cloned into pShuttle using EcoRV/XbaI (pShuttle-Col8A2gRNA). Next, Cas9 DNA (including the promoter and polyadenylation signal) was excised from px330 with NotI/XbaI and cloned into pShuttle-Col8A2gRNA1 (pShuttle-Cas9-Col8A2gRNA1). After linearization with PmeI, pShuttle-Col8A2gRNA was electroporated into BJ5183-AD-1 cells (Agilent Technologies, Santa Clara, CA) and grown on kanamycin LB plates. Small colonies were individually picked and cultured in 5 ml LB medium with kanamycin. After confirming size by digestion with PacI and other restriction enzymes, XL10-Gold Ultracompetent Cells (Agilent Technologies) were transformed with an amplified plasmid of the correct size. The Maxiprep (Qiagen) purified plasmids were linearized by PacI digestion and transfected to AD-293 cells (Agilent Technologies) using Lipofectamine 2000 (Thermo Fisher Scientific). After 14–20 days’ culture, adenovirus generating AD293 cells were harvested. HeLa cells were used to confirm the replication deficiency. The titer of recombinant adenovirus was determined by Adenovirus Functional Titer Immunoassay Kit (Cell Biolabs, Inc, San Diego, CA). The function of Ad-Cas9-Col8a2gRNA was examined using NIH3T3 as described above. For in vivo experiments, further production and purification were performed in a viral core facility at the University of Massachusetts.</p></sec><sec id="s4-6"><title>Anterior chamber injection</title><p>8-week-old male C57BL/6J mice received a single unilateral injection of Ad-Cas9-Col8a2gRNA into the anterior chamber, while the contralateral eye served as a non-injected control. All injections were performed in Animal Biosafety Level 2 Comparative Medicine Core Facility at the University of Utah. Mice were first anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) before topical application of tropicamide and proparacaine. Corneas were punctured 1.5 mm above the limbus with a 31 G needle and the needle gently withdrawn. Using a blunt 33 G Hamilton syringe, Ad-Cas9-Col8a2gRNA (4 μl) was injected through the puncture. To ensure injection delivery, the cannula remained in the anterior chamber for ~5 s after injection before applying erythromycin ophthalmic ointment to the cornea.</p></sec><sec id="s4-7"><title>Measurement of indel rate by deep sequencing</title><p>1-month post Ad-Cas9-Col8a2gRNA injection to C57BL/6J mice, the corneal endothelium was separated mechanically (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). gDNA from the corneal endothelium/stroma was purified by Quick-DNA Microprep Plus Kit (Zymo research). PCRs were performed on the locus using <named-content content-type="sequence">TTCTTCTTCTCCCTGCAGCC</named-content> and <named-content content-type="sequence">GCACATACTTTACCGGGGCA</named-content> (30 cycles, the product size: 155 bp). The deep sequencing was performed by the HSC core at University of Utah. The library was prepared using the Swift Biosciences Accel-NGS 1S Plus DNA Library Kit. The sequence protocol used MiSeq Nano 150 Cycle Paired End Sequencing v2. The total number of reads per file was counted. The reads with median quality scores ≤ 5 were removed from the data set. The reads were aligned to the expected genomic sequence: gi|372099106|ref|NC_000070.6|:126309560–126309770 <italic>Mus musculus</italic> strain C57BL/6J chromosome 4, GRCm38.p4 C57BL/6J.</p></sec><sec id="s4-8"><title>Digenome sequencing </title><sec id="s4-8-1"><title>Human <italic>COL8A2</italic> gRNA design</title><p>We designed two different human Col8a2 gRNAs at the start codon of human <italic>COL8A2</italic> similar to mouse <italic>Col8a2</italic> gRNA.</p><p>HuCol8a2gRNA1 <named-content content-type="sequence">ACGTCCACGGACGCCATGC</named-content>.</p><p>HuCol8a2gRNA2 <named-content content-type="sequence">CGTCCACGGACGCCATGCT</named-content>.</p><p>Underlines indicate the start codon of human <italic>COL8A2</italic>. As explained in the main text, these sequences were cloned into px330 plasmid.</p></sec><sec id="s4-8-2"><title>AD-293 cell culture and plasmid transfection</title><p>To confirm the activity of human gRNAs, we used human AD-293 cells (Agilent), which were maintained following the manufacturer’s instructions. Ca-phosphate method was used for plasmid transfection. Briefly, 0.25 × 10<sup>6</sup> cells were plated in a six-well plate with 2 ml of 10% fetal bovine serum/DMEM. The next day, 6 µg plasmid was transfected. 2 days post transfection, gDNAs were purified with Quick-DNA Plus Kit (Zymo Research, Irvine, CA).</p></sec><sec id="s4-8-3"><title>PCR and restriction enzyme digestion for indel examination</title><p>To examine the indel at the target site, we used PCR and restriction enzyme digestion. PCR primers used were HuCol8a2_F: <named-content content-type="sequence">tgatcttttggtgaccccgg</named-content> and HuCol8a2_R: <named-content content-type="sequence">GGATGTACTTCACTGGGGCA</named-content>. The PCR product (226 bp) was digested with Hin1II, which recognizes CATG. Without indels, the <italic>COL8A2</italic> PCR products were digested to 94 bp and 132 bp. As shown in <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1a</xref>, both px330 plasmid transfections showed the indel. Since we found that HuCol8a2gRNA2 showed slightly higher activity, we proceeded with HuCol8a2gRNA2 for further experiments (mentioned as HuCol8a2gRNA hereafter).</p></sec><sec id="s4-8-4"><title>gRNA production by in vitro transcription</title><p>To produce gRNA, in vitro transcription was performed with MEGAshortscript T7 Transcription Kit (Thermo Fisher). The template DNA was obtained by PCR (Phusion High-Fidelity DNA Polymerase; NEB) with primers forward: <named-content content-type="sequence">TAATACGACTCACTATAGCGTCCACGGACGCCATG</named-content> and reverse: <named-content content-type="sequence">AAAAGCACCGACTCGGTGCCA</named-content> (the underline indicates T7 promoter) using px330-huCol8a2gRNA plasmid as a template. The integrity of gRNA was confirmed by 2% agarose DNA electrophoresis (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1b</xref>).</p></sec><sec id="s4-8-5"><title>In vitro genome digestion with Cas9</title><p>SpCas9 protein was obtained from NEB (M0386M). The reaction was performed in 8 µg gDNA (AD-293), 120 pmol (300 nM) SpCas9, 120 pmol (300 nM), or 360 pmol (900 nM) gRNA with 1X NEBuffer 3.1 (a total volume of 400 µl) at 37°C for 8 hr. After gDNA purification, the digestion at the target site was examined by PCR with HuCol8a2_F and HuCol8a2_R primers (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1c</xref>). We found that 360 pmol gRNA (Cas9: gRNA = 1:3) showed efficient digestion. Therefore, we proceeded with 360 pmol gRNA-treated gDNA for deep sequencing.</p></sec><sec id="s4-8-6"><title>Deep sequencing</title><p>Deep sequencing was performed at the HSC core at the University of Utah. The library was prepared with Illumina TruSeq Nano DNA Sample Prep kit (Illumina, San Diego, CA). The sequence protocol is NovaSeq 2 × 150 bp Sequencing 30X Human Whole Genome.</p></sec><sec id="s4-8-7"><title>Data analysis</title><p>The sequencing data was analyzed at the Bioinformatics core of the University of Utah. As shown in <xref ref-type="fig" rid="fig11">Figure 11a–b</xref>, Cas9-digested gDNA with HuCol8a2 gRNA showed aligned sequencing at the Col8a2 gene target site. On the other hand, control gDNA (Cas9-digested without gRNA) showed random sequencing. Since we found a gap at the target site (<xref ref-type="fig" rid="fig11">Figure 11c</xref>), our analysis accepts the gap, which is explained below.</p><p>The human GRCh38 FASTA file was downloaded from Ensembl and a reference database was created using bowtie2 version 2.3.4. Adapters were trimmed out of reads using Cutadapt 1.16 and then aligned using Bowtie 2 in end-to-end mode (full options --end-to-end --sensitive --no-unal -k 20). The aligned reads were loaded into R using the GenomicAlignments package, and total coverage and read start coverage were calculated for the plus and minus strands. Positions with five or more read starts were compared to the total coverage and read starts with less than 25% of total coverage were removed. The filtered read starts on the positive and negative strands were joined to find predicted cut sites with either no overlap (blunt end), 1 bp gap, or 1 bp overhang.</p></sec></sec><sec id="s4-9"><title>Real-time PCR</title><p>After purification of total RNA from the corneal endothelium and DNase I treatment, cDNA was synthesized with iScript cDNA Synthesis Kit (Biorad). Real-time PCR was conducted using SsoAdvanced Universal SYBR Green Supermix (Biorad) with BioRad CFX96 Real-Time PCR following the manufacture’s protocol (two-step PCR). The following primers were used in this study. Cas9 mRNA and DNA detection, Cas9_forward: <named-content content-type="sequence">CCGAAGAGGTCGTGAAGAAG</named-content> and Cas9_reverse: <named-content content-type="sequence">GCCTTATCCAGTTCGCTCAG</named-content>; gRNA detection, gRNA_forward: <named-content content-type="sequence">AGACGCCATGCGTTTTAGAG</named-content> and gRNA_reverse: <named-content content-type="sequence">CGGTGCCACTTTTTCAAGTT</named-content>; mouse GADPH, mouse GAPDH_forward: <named-content content-type="sequence">AACTTTGGCATTGTGGAAGGGCTC</named-content> and mouse GAPDH_reverse: <named-content content-type="sequence">ACCAGTGGATGCAGGGATGATGTT</named-content>; total mouse Col8a2, mouse Col8a2_forward1: <named-content content-type="sequence">CCACCTACACGTACGACGAA</named-content> and mouse Col8a2_reverse1: <named-content content-type="sequence">ACTCGGTGGAGTAGAGACCA</named-content>; and normal mouse Col8a2, not detection of Col8a2 mRNA with indel, mouse Col8a2_forward2: <named-content content-type="sequence">CCATCCACAGACGCCATG</named-content> and mouse Col8a2_reverse2: <named-content content-type="sequence">GGGCTGCACATACTTTACCG</named-content>.</p></sec><sec id="s4-10"><title>In vivo optical coherence tomography and corneal confocal microscopy</title><p>2 months after anterior chamber injection, corneal thickness was quantified by Spectralis OCT with the anterior-segment OCT module (Heidelberg Engineering, Franklin, MA). An HRT3 Rostock microscope (Heidelberg Engineering) was used to produce serial images of central corneal endothelial density, and endothelial cell counts were performed using ImageJ.</p></sec><sec id="s4-11"><title>Immunohistochemistry and histology</title><p>Immediately following mouse euthanasia, eyes were enucleated and the sclera/retina was punctured to facilitate fixation by immersion in 4% paraformaldehyde/PBS at 4°C. After 2 hr of fixation, the cornea was excised at the limbal boundary, paraffin embedded using standard protocols, and sectioned at 10 μm. For COL8A2 immunostaining, we used avidin-biotin-based detection (Vector Lab Elite ABC kit, Burlingame, CA) with 5 µg/ml rabbit anti-COL8A2 polyclonal antibody (PA5-35077; Thermo Fisher Scientific). 5 µg/ml rabbit IgG was used as an isotype control (02–6102; Thermo Fisher Scientific). After developing with DAB (Vector Lab) and counter-staining with Nuclear Fast Red (Vector Lab), x20 magnified images were obtained with a light microscope (EVOS FL Auto Cell Imaging System; Thermo Fisher Scientific). The intensity of staining was measured by Image J. Briefly, after the color images were converted to the gray scale images, the mean of intensity in corneal epithelium and corneal endothelium was quantified. To compensate for background, the staining intensity in the isotype control was subtracted from each result.</p><p>Masson’s trichrome and Periodic Acid-Schiff (PAS) stainings were performed using Trichrome Stain Kit (Masson, HT15; Sigma-Aldrich, St Louis, MO) and PAS Kit (395B; Sigma-Aldrich), respectively. For corneal endothelial cell density, the whole cornea was fixed with acetone for 1 hr. This and all subsequent washes and incubations were performed at room temperature. After four washes with PBS, the cornea was blocked for 1 hr (3% bovine serum albumin/PBS) and incubated for a further hour with 2.5 µg/ml Alexa Fluor 488 conjugated to anti-ZO1 antibody (339188; Thermo Fisher Scientific). After four final PBS washes, corneas were mounted on glass slides, endothelial side up, and imaged by confocal microscopy (Olympus FluoView FV1000). Corneal endothelial density was calculated manually by counting the number of corneal endothelial cells in three different areas of each cornea.</p><p>For immunostaining on corneal cryosections, we used rat anti-TNFα antibody (clone MP6-XT22; BioLegend, San Diego, CA) and rat anti-IFNγ (clone XMG1.2; BioLegend). As a control, we used isotype antibody (RTK2071; BioLegend). Briefly, the sections were blocked with 5% goat serum, 0.02% triton X-100/PBS for 30 min at room temperature. Then, the sections were stained with antibodies at 5 μg/ml for 1 hr at room temperature. After washing with PBS, the sections were stained with Alexa Fluor 647-conjugated goat anti-rat IgG (H + L) antibody (A-21247; Thermo Fisher Scientific). After DAPI staining, the fluorescence was observed with EVOS microscope.</p></sec><sec id="s4-12"><title>Electroretinography</title><p>C57BL6J mice were injected with Ad-GFP (anterior chamber injection), Ad-Cas9-Col8a2gRNA (anterior chamber injection), or 1 μg concanavalin A (intravitreal injection) (Sigma-Aldrich). The mice were examined with ERG for retinal function safety at 0 (prior to injection), 2, and 4 weeks. Mice were dark-adapted overnight before the experiments and anesthetized with an intraperitoneal injection of tribromoethanol and 2-methyl-2-butanol diluted in physiological saline at 14.5 ml/kg dose. The pupils were dilated with tropicamide (0.5%) and phenylephrine (2.5%) eye drops. ERG experiments were performed with a Ganzfeld ERG (Phoenix Laboratories, Pleasanton, CA). Scotopic combined response was obtained under dark-adapted conditions (no background illumination, 0 cd/m<sup>2</sup>) using white-flash stimuli ranging from −1.7 to 1.0 log cd s/m<sup>2</sup> with 20 responses averaged for each stimulus.</p></sec><sec id="s4-13"><title>Alizarin red staining</title><p>Alizarin red staining for corneal endothelium was performed according to previously published methods (<xref ref-type="bibr" rid="bib31">Taylor and Hunt, 1981</xref>). After euthanizing mice, corneas were harvested and washed twice with saline (0.9% NaCl) prior to a 2 min immersion in 0.2% Alizarin red solution (pH 4.2 adjusted by 0.1% NH<sub>4</sub>OH, in saline). After washing twice again with saline, corneas were fixed with acetone for 10 min and again washed in saline three times (10 min each). Corneas were mounted on glass slides and imaged with a bright-field microscope.</p></sec><sec id="s4-14"><title>Corneal swelling/de-swelling experiment</title><p>Mice were anesthetized with ketamine/xylazine. Imaged corneas were kept moist with Dulbecco’s phosphate-buffered saline (DPBS), excess DPBS was removed with absorbent tissue, while the contralateral eye was covered with an ointment to prevent dehydration. Corneal OCT images were taken before scraping and before treatment. The corneal epithelium was removed mechanically using a Tooke corneal knife (Novo Surgical Inc, Oak Brook, IL) and jeweler’s forceps (<xref ref-type="fig" rid="fig10">Figure 10a</xref>). This process takes about 5 min. For testing the corneal swelling response to different osmolalities of DPBS solution, we sequentially applied solutions at 5 min intervals, beginning with 0 mOsm/l (deionized water) to 900 mOsm/l DPBS, completely covering the eye throughout the course of each application. Each application required 1–2 min for image acquisition with OCT, which was performed immediately after removing the residual solution with a clean absorbent paper. To analyze corneal de-swelling, the cornea was fully covered with 650 mOsm/l DPBS for 10 min. After removing excess solution with a clean filter paper, 4 µl of silicone oil was applied to avoid evaporation from the corneal surface. Corneal and OCT images commenced at 5, 10, 20, 30, 40, and 50 min after the application of DPBS.</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Student’s t-test was used for comparison of averages accompanied with analysis of variance (ANOVA) for multiple group comparisons. To compare the slopes of central corneal thickness trajectory, we employed linear mixed-effects regression approach among groups of C57BL/6J, non-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup>, and Ad-Cas9-Col8a2gRNA-injected <italic>Col8a2</italic><sup>Q455K/Q455K</sup> mice. Random-effect component in the regression approach was used to account for the correlation among repeated measurements within each mouse. The regression analyses were performed using statistical software R at a significance level of 0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the National Institutes of Health/National Eye Institute (R01EY017950), an NIH/NEI core grant, and an unrestricted grant from Research to Prevent Blindness, Inc New York, NY, to the Department of Ophthalmology and Visual Sciences, University of Utah.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Software, Formal analysis, Validation</p></fn><fn fn-type="con" id="con13"><p>Software, Formal analysis, Validation</p></fn><fn fn-type="con" id="con14"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#15-11024 and #18-10016) of the University of Utah.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-55637-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>High-throughput Sequencing data have been deposited in GEO under accession codes GSE146999. Source data files have been provided as excel files.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146999">GSE146999</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afshari</surname> <given-names>NA</given-names></name><name><surname>Igo</surname> <given-names>RP</given-names></name><name><surname>Morris</surname> <given-names>NJ</given-names></name><name><surname>Stambolian</surname> <given-names>D</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Pulagam</surname> <given-names>VL</given-names></name><name><surname>Dunn</surname> <given-names>S</given-names></name><name><surname>Stamler</surname> <given-names>JF</given-names></name><name><surname>Truitt</surname> <given-names>BJ</given-names></name><name><surname>Rimmler</surname> <given-names>J</given-names></name><name><surname>Kuot</surname> <given-names>A</given-names></name><name><surname>Croasdale</surname> <given-names>CR</given-names></name><name><surname>Qin</surname> <given-names>X</given-names></name><name><surname>Burdon</surname> <given-names>KP</given-names></name><name><surname>Riazuddin</surname> <given-names>SA</given-names></name><name><surname>Mills</surname> <given-names>R</given-names></name><name><surname>Klebe</surname> <given-names>S</given-names></name><name><surname>Minear</surname> <given-names>MA</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Balajonda</surname> <given-names>E</given-names></name><name><surname>Rosenwasser</surname> <given-names>GO</given-names></name><name><surname>Baratz</surname> <given-names>KH</given-names></name><name><surname>Mootha</surname> <given-names>VV</given-names></name><name><surname>Patel</surname> <given-names>SV</given-names></name><name><surname>Gregory</surname> <given-names>SG</given-names></name><name><surname>Bailey-Wilson</surname> <given-names>JE</given-names></name><name><surname>Price</surname> <given-names>MO</given-names></name><name><surname>Price</surname> <given-names>FW</given-names></name><name><surname>Craig</surname> <given-names>JE</given-names></name><name><surname>Fingert</surname> <given-names>JH</given-names></name><name><surname>Gottsch</surname> <given-names>JD</given-names></name><name><surname>Aldave</surname> <given-names>AJ</given-names></name><name><surname>Klintworth</surname> <given-names>GK</given-names></name><name><surname>Lass</surname> <given-names>JH</given-names></name><name><surname>Li</surname> <given-names>YJ</given-names></name><name><surname>Iyengar</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-wide association study identifies three novel loci in fuchs endothelial corneal dystrophy</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14898</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14898</pub-id><pub-id pub-id-type="pmid">28358029</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldave</surname> <given-names>AJ</given-names></name><name><surname>Han</surname> <given-names>J</given-names></name><name><surname>Frausto</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics of the corneal endothelial dystrophies: an evidence-based review</article-title><source>Clinical Genetics</source><volume>84</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1111/cge.12191</pub-id><pub-id pub-id-type="pmid">23662738</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartonicek</surname> <given-names>N</given-names></name><name><surname>Clark</surname> <given-names>MB</given-names></name><name><surname>Quek</surname> <given-names>XC</given-names></name><name><surname>Torpy</surname> <given-names>JR</given-names></name><name><surname>Pritchard</surname> <given-names>AL</given-names></name><name><surname>Maag</surname> <given-names>JLV</given-names></name><name><surname>Gloss</surname> <given-names>BS</given-names></name><name><surname>Crawford</surname> <given-names>J</given-names></name><name><surname>Taft</surname> <given-names>RJ</given-names></name><name><surname>Hayward</surname> <given-names>NK</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Mattick</surname> <given-names>JS</given-names></name><name><surname>Mercer</surname> <given-names>TR</given-names></name><name><surname>Dinger</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Intergenic disease-associated regions are abundant in novel transcripts</article-title><source>Genome Biology</source><volume>18</volume><elocation-id>241</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-017-1363-3</pub-id><pub-id pub-id-type="pmid">29284497</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>S</given-names></name><name><surname>Munier</surname> <given-names>FL</given-names></name><name><surname>Yardley</surname> <given-names>J</given-names></name><name><surname>Hart-Holden</surname> <given-names>N</given-names></name><name><surname>Perveen</surname> <given-names>R</given-names></name><name><surname>Cousin</surname> <given-names>P</given-names></name><name><surname>Sutphin</surname> <given-names>JE</given-names></name><name><surname>Noble</surname> <given-names>B</given-names></name><name><surname>Batterbury</surname> <given-names>M</given-names></name><name><surname>Kielty</surname> <given-names>C</given-names></name><name><surname>Hackett</surname> <given-names>A</given-names></name><name><surname>Bonshek</surname> <given-names>R</given-names></name><name><surname>Ridgway</surname> <given-names>A</given-names></name><name><surname>McLeod</surname> <given-names>D</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name><name><surname>Schorderet</surname> <given-names>DF</given-names></name><name><surname>Black</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy</article-title><source>Human Molecular Genetics</source><volume>10</volume><fpage>2415</fpage><lpage>2423</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.21.2415</pub-id><pub-id pub-id-type="pmid">11689488</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonanno</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular mechanisms underlying the corneal endothelial pump</article-title><source>Experimental Eye Research</source><volume>95</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2011.06.004</pub-id><pub-id pub-id-type="pmid">21693119</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeau</surname> <given-names>PM</given-names></name><name><surname>Lu</surname> <given-names>JT</given-names></name><name><surname>Dawson</surname> <given-names>BC</given-names></name><name><surname>Fokkema</surname> <given-names>IF</given-names></name><name><surname>Robertson</surname> <given-names>SP</given-names></name><name><surname>Gibbs</surname> <given-names>RA</given-names></name><name><surname>Lee</surname> <given-names>BH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The <italic>KAT6B</italic>-related disorders genitopatellar syndrome and ohdo/SBBYS syndrome have distinct clinical features reflecting distinct molecular mechanisms</article-title><source>Human Mutation</source><volume>33</volume><fpage>1520</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1002/humu.22141</pub-id><pub-id pub-id-type="pmid">22715153</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Barretto</surname> <given-names>R</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname> <given-names>AR</given-names></name><name><surname>Stout</surname> <given-names>KA</given-names></name><name><surname>Ozawa</surname> <given-names>M</given-names></name><name><surname>Lohr</surname> <given-names>KM</given-names></name><name><surname>Hoffman</surname> <given-names>CA</given-names></name><name><surname>Bernstein</surname> <given-names>AI</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Sgobio</surname> <given-names>C</given-names></name><name><surname>Sastry</surname> <given-names>N</given-names></name><name><surname>Cai</surname> <given-names>H</given-names></name><name><surname>Caudle</surname> <given-names>WM</given-names></name><name><surname>Miller</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease</article-title><source>PNAS</source><volume>114</volume><fpage>E2253</fpage><lpage>E2262</lpage><pub-id pub-id-type="doi">10.1073/pnas.1616892114</pub-id><pub-id pub-id-type="pmid">28246328</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="book"><person-group person-group-type="author"><collab>EBAA</collab></person-group><year iso-8601-date="2016">2016</year><source>Eye Banking Stastical Report</source><publisher-name>98 (Eye Bank Association of America, Washington DC, 2017)</publisher-name></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottsch</surname> <given-names>JD</given-names></name><name><surname>Sundin</surname> <given-names>OH</given-names></name><name><surname>Liu</surname> <given-names>SH</given-names></name><name><surname>Jun</surname> <given-names>AS</given-names></name><name><surname>Broman</surname> <given-names>KW</given-names></name><name><surname>Stark</surname> <given-names>WJ</given-names></name><name><surname>Vito</surname> <given-names>EC</given-names></name><name><surname>Narang</surname> <given-names>AK</given-names></name><name><surname>Thompson</surname> <given-names>JM</given-names></name><name><surname>Magovern</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inheritance of a novel <italic>COL8A2</italic> mutation defines a distinct early-onset subtype of fuchs corneal dystrophy</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>46</volume><fpage>1934</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-0937</pub-id><pub-id pub-id-type="pmid">15914606</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopfer</surname> <given-names>U</given-names></name><name><surname>Fukai</surname> <given-names>N</given-names></name><name><surname>Hopfer</surname> <given-names>H</given-names></name><name><surname>Wolf</surname> <given-names>G</given-names></name><name><surname>Joyce</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>E</given-names></name><name><surname>Olsen</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Targeted disruption of <italic>Col8a1</italic> and <italic>Col8a2</italic> genes in mice leads to anterior segment abnormalities in the eye</article-title><source>The FASEB Journal</source><volume>19</volume><fpage>1232</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1096/fj.04-3019com</pub-id><pub-id pub-id-type="pmid">16051690</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igo</surname> <given-names>RP</given-names></name><name><surname>Kopplin</surname> <given-names>LJ</given-names></name><name><surname>Joseph</surname> <given-names>P</given-names></name><name><surname>Truitt</surname> <given-names>B</given-names></name><name><surname>Fondran</surname> <given-names>J</given-names></name><name><surname>Bardenstein</surname> <given-names>D</given-names></name><name><surname>Aldave</surname> <given-names>AJ</given-names></name><name><surname>Croasdale</surname> <given-names>CR</given-names></name><name><surname>Price</surname> <given-names>MO</given-names></name><name><surname>Rosenwasser</surname> <given-names>M</given-names></name><name><surname>Lass</surname> <given-names>JH</given-names></name><name><surname>Iyengar</surname> <given-names>SK</given-names></name><collab>FECD Genetics Multi-center Study Group</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Differing roles for TCF4 and COL8A2 in central corneal thickness and Fuchs endothelial corneal dystrophy</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e46742</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046742</pub-id><pub-id pub-id-type="pmid">23110055</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname> <given-names>AS</given-names></name><name><surname>Meng</surname> <given-names>H</given-names></name><name><surname>Ramanan</surname> <given-names>N</given-names></name><name><surname>Matthaei</surname> <given-names>M</given-names></name><name><surname>Chakravarti</surname> <given-names>S</given-names></name><name><surname>Bonshek</surname> <given-names>R</given-names></name><name><surname>Black</surname> <given-names>GC</given-names></name><name><surname>Grebe</surname> <given-names>R</given-names></name><name><surname>Kimos</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An alpha 2 collagen VIII transgenic knock-in mouse model of fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr473</pub-id><pub-id pub-id-type="pmid">22002996</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Bae</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>HR</given-names></name><name><surname>Hwang</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>JI</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells</article-title><source>Nature Methods</source><volume>12</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3284</pub-id><pub-id pub-id-type="pmid">25664545</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozak</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Point mutations close to the AUG initiator Codon affect the efficiency of translation of rat preproinsulin in vivo</article-title><source>Nature</source><volume>308</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/308241a0</pub-id><pub-id pub-id-type="pmid">6700727</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuot</surname> <given-names>A</given-names></name><name><surname>Hewitt</surname> <given-names>AW</given-names></name><name><surname>Snibson</surname> <given-names>GR</given-names></name><name><surname>Souzeau</surname> <given-names>E</given-names></name><name><surname>Mills</surname> <given-names>R</given-names></name><name><surname>Craig</surname> <given-names>JE</given-names></name><name><surname>Burdon</surname> <given-names>KP</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TGC repeat expansion in the TCF4 gene increases the risk of Fuchs' endothelial corneal dystrophy in Australian cases</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0183719</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0183719</pub-id><pub-id pub-id-type="pmid">28832669</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Deng</surname> <given-names>ZL</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Tang</surname> <given-names>N</given-names></name><name><surname>Song</surname> <given-names>WX</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Sharff</surname> <given-names>KA</given-names></name><name><surname>Luu</surname> <given-names>HH</given-names></name><name><surname>Haydon</surname> <given-names>RC</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>He</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A protocol for rapid generation of recombinant adenoviruses using the AdEasy system</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1236</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.135</pub-id><pub-id pub-id-type="pmid">17546019</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mali</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Esvelt</surname> <given-names>KM</given-names></name><name><surname>Aach</surname> <given-names>J</given-names></name><name><surname>Guell</surname> <given-names>M</given-names></name><name><surname>DiCarlo</surname> <given-names>JE</given-names></name><name><surname>Norville</surname> <given-names>JE</given-names></name><name><surname>Church</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RNA-guided human genome engineering via Cas9</article-title><source>Science</source><volume>339</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1126/science.1232033</pub-id><pub-id pub-id-type="pmid">23287722</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthaei</surname> <given-names>M</given-names></name><name><surname>Meng</surname> <given-names>H</given-names></name><name><surname>Meeker</surname> <given-names>AK</given-names></name><name><surname>Eberhart</surname> <given-names>CG</given-names></name><name><surname>Jun</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endothelial <italic>Cdkn1a</italic> (<italic>p21</italic>) overexpression and accelerated senescence in a mouse model of fuchs endothelial corneal dystrophy</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>6718</fpage><lpage>6727</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9669</pub-id><pub-id pub-id-type="pmid">22956607</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>H</given-names></name><name><surname>Matthaei</surname> <given-names>M</given-names></name><name><surname>Ramanan</surname> <given-names>N</given-names></name><name><surname>Grebe</surname> <given-names>R</given-names></name><name><surname>Chakravarti</surname> <given-names>S</given-names></name><name><surname>Speck</surname> <given-names>CL</given-names></name><name><surname>Kimos</surname> <given-names>M</given-names></name><name><surname>Vij</surname> <given-names>N</given-names></name><name><surname>Eberhart</surname> <given-names>CG</given-names></name><name><surname>Jun</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>L450W and Q455K <italic>Col8a2</italic> knock-in mouse models of fuchs endothelial corneal dystrophy show distinct phenotypes and evidence for altered autophagy</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>54</volume><fpage>1887</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-11021</pub-id><pub-id pub-id-type="pmid">23422828</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitry</surname> <given-names>D</given-names></name><name><surname>Bhogal</surname> <given-names>M</given-names></name><name><surname>Patel</surname> <given-names>AK</given-names></name><name><surname>Lee</surname> <given-names>BS</given-names></name><name><surname>Chai</surname> <given-names>SM</given-names></name><name><surname>Price</surname> <given-names>MO</given-names></name><name><surname>Price</surname> <given-names>FW</given-names></name><name><surname>Jun</surname> <given-names>AS</given-names></name><name><surname>Aldave</surname> <given-names>AJ</given-names></name><name><surname>Mehta</surname> <given-names>JS</given-names></name><name><surname>Busin</surname> <given-names>M</given-names></name><name><surname>Allan</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome</article-title><source>JAMA Ophthalmology</source><volume>132</volume><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2014.352</pub-id><pub-id pub-id-type="pmid">24763830</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname> <given-names>VV</given-names></name><name><surname>Hussain</surname> <given-names>I</given-names></name><name><surname>Cunnusamy</surname> <given-names>K</given-names></name><name><surname>Graham</surname> <given-names>E</given-names></name><name><surname>Gong</surname> <given-names>X</given-names></name><name><surname>Neelam</surname> <given-names>S</given-names></name><name><surname>Xing</surname> <given-names>C</given-names></name><name><surname>Kittler</surname> <given-names>R</given-names></name><name><surname>Petroll</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>TCF4</italic> triplet repeat expansion and nuclear RNA foci in Fuchs' Endothelial corneal dystrophy</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>2003</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-16222</pub-id><pub-id pub-id-type="pmid">25722209</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname> <given-names>M</given-names></name><name><surname>Okumura</surname> <given-names>N</given-names></name><name><surname>Nakagawa</surname> <given-names>H</given-names></name><name><surname>Koizumi</surname> <given-names>N</given-names></name><name><surname>Ikeda</surname> <given-names>Y</given-names></name><name><surname>Ueno</surname> <given-names>M</given-names></name><name><surname>Yoshii</surname> <given-names>K</given-names></name><name><surname>Adachi</surname> <given-names>H</given-names></name><name><surname>Aleff</surname> <given-names>RA</given-names></name><name><surname>Butz</surname> <given-names>ML</given-names></name><name><surname>Highsmith</surname> <given-names>WE</given-names></name><name><surname>Tashiro</surname> <given-names>K</given-names></name><name><surname>Wieben</surname> <given-names>ED</given-names></name><name><surname>Kinoshita</surname> <given-names>S</given-names></name><name><surname>Baratz</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Trinucleotide repeat expansion in the <italic>TCF4</italic> Gene in Fuchs' Endothelial Corneal Dystrophy in Japanese</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>4865</fpage><lpage>4869</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-17082</pub-id><pub-id pub-id-type="pmid">26218914</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanda</surname> <given-names>GG</given-names></name><name><surname>Padhy</surname> <given-names>B</given-names></name><name><surname>Samal</surname> <given-names>S</given-names></name><name><surname>Das</surname> <given-names>S</given-names></name><name><surname>Alone</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic association of <italic>TCF4</italic> intronic polymorphisms, CTG18.1 and rs17089887, with Fuchs' endothelial corneal dystrophy in an Indian population</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>55</volume><fpage>7674</fpage><lpage>7680</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-15297</pub-id><pub-id pub-id-type="pmid">25342617</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname> <given-names>J</given-names></name><name><surname>Mikuni</surname> <given-names>T</given-names></name><name><surname>Yasuda</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Virus-Mediated genome editing via Homology-Directed repair in Mitotic and postmitotic cells in mammalian brain</article-title><source>Neuron</source><volume>96</volume><fpage>755</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.10.004</pub-id><pub-id pub-id-type="pmid">29056297</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagopoulos</surname> <given-names>I</given-names></name><name><surname>Fioretos</surname> <given-names>T</given-names></name><name><surname>Isaksson</surname> <given-names>M</given-names></name><name><surname>Samuelsson</surname> <given-names>U</given-names></name><name><surname>Billström</surname> <given-names>R</given-names></name><name><surname>Strömbeck</surname> <given-names>B</given-names></name><name><surname>Mitelman</surname> <given-names>F</given-names></name><name><surname>Johansson</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)</article-title><source>Human Molecular Genetics</source><volume>10</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.4.395</pub-id><pub-id pub-id-type="pmid">11157802</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riazuddin</surname> <given-names>SA</given-names></name><name><surname>Zaghloul</surname> <given-names>NA</given-names></name><name><surname>Al-Saif</surname> <given-names>A</given-names></name><name><surname>Davey</surname> <given-names>L</given-names></name><name><surname>Diplas</surname> <given-names>BH</given-names></name><name><surname>Meadows</surname> <given-names>DN</given-names></name><name><surname>Eghrari</surname> <given-names>AO</given-names></name><name><surname>Minear</surname> <given-names>MA</given-names></name><name><surname>Li</surname> <given-names>YJ</given-names></name><name><surname>Klintworth</surname> <given-names>GK</given-names></name><name><surname>Afshari</surname> <given-names>N</given-names></name><name><surname>Gregory</surname> <given-names>SG</given-names></name><name><surname>Gottsch</surname> <given-names>JD</given-names></name><name><surname>Katsanis</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Missense mutations in TCF8 cause late-onset fuchs corneal dystrophy and interact with FCD4 on chromosome 9p</article-title><source>The American Journal of Human Genetics</source><volume>86</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.12.001</pub-id><pub-id pub-id-type="pmid">20036349</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rual</surname> <given-names>JF</given-names></name><name><surname>Hirozane-Kishikawa</surname> <given-names>T</given-names></name><name><surname>Hao</surname> <given-names>T</given-names></name><name><surname>Bertin</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Dricot</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Rosenberg</surname> <given-names>J</given-names></name><name><surname>Lamesch</surname> <given-names>P</given-names></name><name><surname>Vidalain</surname> <given-names>PO</given-names></name><name><surname>Clingingsmith</surname> <given-names>TR</given-names></name><name><surname>Hartley</surname> <given-names>JL</given-names></name><name><surname>Esposito</surname> <given-names>D</given-names></name><name><surname>Cheo</surname> <given-names>D</given-names></name><name><surname>Moore</surname> <given-names>T</given-names></name><name><surname>Simmons</surname> <given-names>B</given-names></name><name><surname>Sequerra</surname> <given-names>R</given-names></name><name><surname>Bosak</surname> <given-names>S</given-names></name><name><surname>Doucette-Stamm</surname> <given-names>L</given-names></name><name><surname>Le Peuch</surname> <given-names>C</given-names></name><name><surname>Vandenhaute</surname> <given-names>J</given-names></name><name><surname>Cusick</surname> <given-names>ME</given-names></name><name><surname>Albala</surname> <given-names>JS</given-names></name><name><surname>Hill</surname> <given-names>DE</given-names></name><name><surname>Vidal</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human ORFeome version 1.1: a platform for reverse proteomics</article-title><source>Genome Research</source><volume>14</volume><fpage>2128</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1101/gr.2973604</pub-id><pub-id pub-id-type="pmid">15489335</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname> <given-names>JF</given-names></name><name><surname>Roos</surname> <given-names>BR</given-names></name><name><surname>Wagoner</surname> <given-names>MD</given-names></name><name><surname>Goins</surname> <given-names>KM</given-names></name><name><surname>Kitzmann</surname> <given-names>AS</given-names></name><name><surname>Riley</surname> <given-names>JB</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name><name><surname>Fingert</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Confirmation of the association between the <italic>TCF4</italic> risk allele and Fuchs endothelial corneal dystrophy in patients from the Midwestern United States</article-title><source>Ophthalmic Genetics</source><volume>34</volume><fpage>32</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3109/13816810.2012.726396</pub-id><pub-id pub-id-type="pmid">22998502</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugar</surname> <given-names>A</given-names></name><name><surname>Gal</surname> <given-names>RL</given-names></name><name><surname>Kollman</surname> <given-names>C</given-names></name><name><surname>Raghinaru</surname> <given-names>D</given-names></name><name><surname>Dontchev</surname> <given-names>M</given-names></name><name><surname>Croasdale</surname> <given-names>CR</given-names></name><name><surname>Feder</surname> <given-names>RS</given-names></name><name><surname>Holland</surname> <given-names>EJ</given-names></name><name><surname>Lass</surname> <given-names>JH</given-names></name><name><surname>Macy</surname> <given-names>JI</given-names></name><name><surname>Mannis</surname> <given-names>MJ</given-names></name><name><surname>Smith</surname> <given-names>PW</given-names></name><name><surname>Soukiasian</surname> <given-names>SH</given-names></name><name><surname>Beck</surname> <given-names>RW</given-names></name><collab>Writing Committee for the Cornea Donor Study Research Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Factors associated with corneal graft survival in the cornea donor study</article-title><source>JAMA Ophthalmology</source><volume>133</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2014.3923</pub-id><pub-id pub-id-type="pmid">25322173</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>MJ</given-names></name><name><surname>Hunt</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Dual staining of corneal endothelium with trypan blue and alizarin red S: importance of pH for the dye-lake reaction</article-title><source>British Journal of Ophthalmology</source><volume>65</volume><fpage>815</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1136/bjo.65.12.815</pub-id><pub-id pub-id-type="pmid">6172144</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vedana</surname> <given-names>G</given-names></name><name><surname>Villarreal</surname> <given-names>G</given-names></name><name><surname>Jun</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fuchs endothelial corneal dystrophy: current perspectives</article-title><source>Clinical Ophthalmology</source><volume>10</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.2147/OPTH.S83467</pub-id><pub-id pub-id-type="pmid">26937169</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieben</surname> <given-names>ED</given-names></name><name><surname>Aleff</surname> <given-names>RA</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Kalari</surname> <given-names>KR</given-names></name><name><surname>Maguire</surname> <given-names>LJ</given-names></name><name><surname>Patel</surname> <given-names>SV</given-names></name><name><surname>Baratz</surname> <given-names>KH</given-names></name><name><surname>Fautsch</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gene expression in the corneal endothelium of fuchs endothelial corneal dystrophy patients with and without expansion of a trinucleotide repeat in TCF4</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0200005</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0200005</pub-id><pub-id pub-id-type="pmid">29966009</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieben</surname> <given-names>ED</given-names></name><name><surname>Baratz</surname> <given-names>KH</given-names></name><name><surname>Aleff</surname> <given-names>RA</given-names></name><name><surname>Kalari</surname> <given-names>KR</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Maguire</surname> <given-names>LJ</given-names></name><name><surname>Patel</surname> <given-names>SV</given-names></name><name><surname>Fautsch</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gene expression and missplicing in the corneal endothelium of patients with a TCF4 trinucleotide repeat expansion without Fuchs' Endothelial corneal dystrophy</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>60</volume><fpage>3636</fpage><lpage>3643</lpage><pub-id pub-id-type="doi">10.1167/iovs.19-27689</pub-id><pub-id pub-id-type="pmid">31469403</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Mookherjee</surname> <given-names>S</given-names></name><name><surname>Chaitankar</surname> <given-names>V</given-names></name><name><surname>Hiriyanna</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>JW</given-names></name><name><surname>Brooks</surname> <given-names>M</given-names></name><name><surname>Ataeijannati</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Dong</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Swaroop</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14716</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14716</pub-id><pub-id pub-id-type="pmid">28291770</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Ming</surname> <given-names>C</given-names></name><name><surname>Fu</surname> <given-names>X</given-names></name><name><surname>Duan</surname> <given-names>Y</given-names></name><name><surname>Hoang</surname> <given-names>DA</given-names></name><name><surname>Rutgard</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Hou</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>E</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Hao</surname> <given-names>X</given-names></name><name><surname>Xiong</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors</article-title><source>Cell Research</source><volume>27</volume><fpage>830</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.57</pub-id><pub-id pub-id-type="pmid">28429769</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55637.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Cepko</surname><given-names>Constance L</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ksander</surname><given-names>Bruce</given-names> </name><role>Reviewer</role><aff><institution>Mass Eye and Ear Infirmary</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Repair of any genetic disease is of interest, and Uehara have shown an improvement in corneal tissue architecture and function in a mouse model of Fuchs' Dystrophy using gene editing delivered by adenovirus to the corneal endothelium. Editing led to the loss of collagen protein, which is the pathogenic protein in this disease. Indel frequency was very high in the endothelium while the stroma and epithelium showed no editing due to the delivery of the vector to the endothelium alone. The results show promise for this method in the treatment of corneal endothelial disease, perhaps replacing or delaying a need for a corneal transplant.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Bruce Ksander (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>Repair of any genetic disease is of interest, and Uehara have shown an improvement in corneal tissue architecture and function in a mouse model of Fuchs' Dystrophy using gene editing delivered by adenovirus. They have improved their study to address several issues raised in the previous review. However, the current review raises a number of important points. A quantitative assessment of Col protein level relative to the expression of Cas9 and gRNA (Reviewer 1, point 2) would strengthen the data shown in Figure 3, as was also suggested by Reviewer 2 (point 1), and must be carried out. This would also help the argument presented by authors regarding genomic DNA contamination that was indirectly addressed by Sup. Figure 2. Although not required, it is recommended that the question of inflammation and/or effects on gene expression by the adenovirus be addressed more thoroughly, by sequencing or by a more thorough evaluation of gene expression changes. This is an issue as Adenovirus is known to incite pathological inflammatory effects. Finally, again not required by recommended, the authors are encouraged to assay for a correction of the UPR.</p><p>Essential revisions:</p><p>Please quantify the levels of collage protein.</p><p><italic>Reviewer #1:</italic></p><p>The study by Uehara et al. titled &quot;Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy&quot; describes a strategy for resolving a dominant negative disease phenotype by CRISPR/Cas9 targeting of the start codon of the causative gene, Col8a2. The authors employ recombinant adenovirus packaging SpCas9 and a single gRNA targeting the start codon of the Col8a2 ORF. in vivo efficacy in wild type mice correlates with a qualitative reduction in COL8A2 expression in these mice by immunostaining. Using a mouse model homozygous for a causative mutation, Col8a2Q455K/Q455K, the authors show a significant reduction in disease pathology, qualitatively via tissue architecture and quantitatively by assaying corneal endothelial pump function. Off-target effects are modeled in vitro and identify several sites, but no significant concerns noted. Overall, the study provides proof-of-concept and feasibility of utilizing this approach, with significant possible outcomes for FECD. Significant concerns pertaining to cassette design, data analysis and additional experiments are highlighted below.</p><p>1. The vector construct utilizes a ubiquitous promoter, Chicken beta actin (truncated) to drive Cas9 expression and a U6 promoter to drive guide RNA. It is unclear why the authors only see a qualitative effect on protein knockdown by immunostaining in the endothelium. Does Adenovirus not infect underlying stromal or epithelial cells? The presence/absence of Ad DNA in these other cells has not been evaluated.</p><p>2. A correlation between expression of Cas9, gRNA and COL8A2 (protein and mRNA) would be important to establish in mice. This is especially critical to demonstrate in the disease model not only to correlate protein knockdown with restored function, but because the efficiency of Ad infection or gene editing could vary in diseased cells.</p><p>3. The authors note that the indel frequency, determined by deep sequencing, appears inconsistent with the observed protein knockdown as determined by immunostaining of tissue sections. However, while the indel frequency is determined quantitatively (~20-25%), but the protein and mRNA levels are not quantified. Is the half-life of wt and mutant COL8A2 known? The authors also report an editing normalized indel rate of 102% in endothelial cells. While the hypothesis of gDNA contamination from non-targeted tissue is likely true (supported by experimental evidence from Supplemental Figure 2), the method used for correction is insufficient to be used to report a true, corrected indel frequency.</p><p>4. Overall what is the minimum/threshold % of endothelial cells that need to be edited to restore function? This information will be critical in designing vector dose and altering promoter strength/specificity to reduce off-target effects. While the impact of vector dose on COL8A2 expression knockdown is assessed, data pertaining to off-target effects at different doses are not presented.</p><p>5. Does overexpression of spCas9, gRNA and knockdown of COL8A2 affect the expression of other genes in the endothelium? The authors analyze the impact of Ad dosing at the inflammatory level, but consequences of control vs treatment vector on endothelial cell gene expression have not been evaluated (e.g., Yu et al., Nat Commun, 2017).</p><p><italic>Reviewer #2:</italic></p><p>This is an interesting study demonstrating the use of CRISPR/Cas9 to prevent development of Fuchs' corneal dystrophy in a mouse model in which the human mutation (Q455K / Q455K) was knocked into the Col8a2 gene. This gene mutation has been previously shown to induce early-onset Fuchs' dystrophy in patients. This is an important observation with translational potential to treat a subpopulation of patients with Fuchs' dystrophy.</p><p>In general, the data support the author's conclusion that Adenovirus-Cas9-gRNA restores the phenotype in adult post-mitotic cells.</p><p>I have a two major questions / issues:</p><p>1. The data presented in Figure 3 are critical to the paper and show that Ad-Cas9-Col8a2gRNA treatment reduces expression of the Col8A2 protein in corneal endothelial cells. However, there is no quantitative assessment of the protein reduction other than the images presented from three cross sections. Since Figure 2a indicates the transduction of the corneal endothelial cells is not evenly distributed, some type of quantitative assessment is needed for Figure 3, either measuring the antibody staining in numerous sections from several different corneas, or by western blot. This is necessary, even though there is quantitative assessment of the change in phenotype of the treated corneas (corneal endothelial cell density, morphology, and guttae-like lesion expression).</p><p>2. To demonstrate that Ad-Cas9-Col8a2gRNA treatment rescued corneal endothelial cell function in the mutant mice, the authors developed an assay that measured the ability of endothelial cell pump function to reduce swelling of the stroma after the corneas were induced to swell by adding hypertonic solutions. While this assay does measure pump function, there is a more direct measure of mutant corneal endothelial cells. The investigators that created the Col8A2 (Q455K / Q455K) mutant mice demonstrated the mutation caused an activation of UPR (unfolded protein response) as shown by an increase in Grp78 and Grp153 in corneal endothelial cells. In my opinion, demonstrating rescue of this function in the mutant mice would have been significantly more impressive.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55637.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Summary:</p><p>Repair of any genetic disease is of interest, and Uehara have shown an improvement in corneal tissue architecture and function in a mouse model of Fuchs' Dystrophy using gene editing delivered by adenovirus. They have improved their study to address several issues raised in the previous review. However, the current review raises a number of important points. A quantitative assessment of Col protein level relative to the expression of Cas9 and gRNA (Reviewer 1, point 2) would strengthen the data shown in Figure 3, as was also suggested by Reviewer 2 (point 1), and must be carried out. This would also help the argument presented by authors regarding genomic DNA contamination that was indirectly addressed by Sup. Figure 2.</p></disp-quote><p>COL8A2 protein quantification</p><p>We agree with the reviewer(s) that quantification and comparison of COL8A2 protein levels with Cas9 and gRNA expression enhances our findings.(Figure 3—figure supplement 1 and Figure 6). COL8A2 staining intensity in the endothelium was calculated from immunostaining (Figure 3—figure supplement 1A). Since staining intensity and image background varied, we normalized the staining intensity of corneal endothelium to that of corneal epithelium as a reference (Figure 3—figure supplement 1B). With injection of medium (6.3 x 10<sup>6</sup> vg) or high (25 x 10<sup>6</sup> vg) doses of adenovirus, COL8A2 endothelial expression in the endothelium decreased significantly.</p><p>Cas9 and gRNA expression.</p><p>To examine Cas9 and gRNA expression, we purified the total RNA from the corneal endothelium one week after anterior chamber injection of each dose of Ad-Cas9-Col8a2gRNA and determined the expression by real time PCR (Figure 6A and B). <italic>Col8a2</italic> expression is compared to GAPDH using delta Ct. Expression values for undetectable samples were recorded as zero. Cas9 and gRNA were both expressed at levels positively correlated with injection dose.</p><p>Indel rate of <italic>Col8a2</italic> mRNA</p><p>To examine the correlation between the indel rate in <italic>Col8a2</italic> mRNA and Cas9/gRNA expression, we designed two sets of real time PCR primers. One was designed at the unrelated position of gRNA target. This set of primers detected total <italic>Col8a2</italic> mRNA with and without indels. The other primer set was designed at the indel site, which does not detect <italic>Col8a2</italic> mRNA with indel but detects normal <italic>Col8a2</italic> mRNA without indels. In C57BL/6J mice, the normal <italic>Col8a2</italic> mRNA (no indel) rates were 58.7 ± 11.4% (6.3 x 10<sup>6</sup> vg) and 56.1 ± 42.9% (25 x 10<sup>6</sup> vg), while in <italic>Col8a2</italic><sup>Q455K</sup> mice, the normal <italic>Col8a2</italic> mRNA (no indel) rates were 67.5 ± 19.0% (6.3 x 10<sup>6</sup> vg) and 35.4 ± 33.3% (25 x 10<sup>6</sup> vg). Cas9 and gRNA were positively correlated (Figure 6D). Contrarily, Cas9/gRNA and normal <italic>Col8a2</italic> mRNA (no indel) were inversely correlated (Figure 6E and F). Hence, indel efficiency is correlated to Cas9/gRNA expression, which can be controlled by the dose of adenovirus injected.</p><disp-quote content-type="editor-comment"><p>Although not required, it is recommended that the question of inflammation and/or effects on gene expression by the adenovirus be addressed more thoroughly, by sequencing or by a more thorough evaluation of gene expression changes. This is an issue as Adenovirus is known to incite pathological inflammatory effects. Finally, again not required by recommended, the authors are encouraged to assay for a correction of the UPR.</p></disp-quote><p>We assessed inflammation and presented the results in manuscript (see page 6-7, Figure 4 and Figure 4—figure supplement 1-4). Future studies will explore RNA-Seq on a variety of genes and effects on the UPR. We have added text in the discussion to this effect.</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Please quantify the levels of collage protein.</p></disp-quote><p>As per the reviewer’s request, we quantified the levels of COL8A2 (Figure 3—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>The study by Uehara et al. titled &quot;Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy&quot; describes a strategy for resolving a dominant negative disease phenotype by CRISPR/Cas9 targeting of the start codon of the causative gene, Col8a2. The authors employ recombinant adenovirus packaging SpCas9 and a single gRNA targeting the start codon of the Col8a2 ORF. in vivo efficacy in wild type mice correlates with a qualitative reduction in COL8A2 expression in these mice by immunostaining. Using a mouse model homozygous for a causative mutation, Col8a2Q455K/Q455K, the authors show a significant reduction in disease pathology, qualitatively via tissue architecture and quantitatively by assaying corneal endothelial pump function. Off-target effects are modeled in vitro and identify several sites, but no significant concerns noted. Overall, the study provides proof-of-concept and feasibility of utilizing this approach, with significant possible outcomes for FECD. Significant concerns pertaining to cassette design, data analysis and additional experiments are highlighted below.</p><p>1. The vector construct utilizes a ubiquitous promoter, Chicken beta actin (truncated) to drive Cas9 expression and a U6 promoter to drive guide RNA. It is unclear why the authors only see a qualitative effect on protein knockdown by immunostaining in the endothelium. Does Adenovirus not infect underlying stromal or epithelial cells? The presence/absence of Ad DNA in these other cells has not been evaluated.</p></disp-quote><p>This is a valid point for which we thank the reviewer. In this study, our primary purpose is to determine whether the CRISPR/Cas9 system via adenoviral vector can be applied to the corneal endothelium. In the future, we will develop an adenovirus with endothelial specific promoter such as NSE. In the present study, as the adenovirus is injected into the anterior chamber, the adenovirus would not cross from the intracameral cavity to the corneal stroma. It is possible that a small amount adenovirus may leak from the injection site and proceed to transfect corneal epithelium. However, the corneal epithelium is continuously regenerating (with epithelial turnover in mice reported as quickly as 2 or 3 days), in contrast to endothelial cells which are post-mitotic.</p><p>To confirm this line of reasoning, we examined whether the adenovirus genome can be detected in corneal stroma/epithelium and endothelium by PCR (Figure 2—figure supplement 3). The adenovirus genome was detected only in the endothelium.</p><disp-quote content-type="editor-comment"><p>2. A correlation between expression of Cas9, gRNA and COL8A2 (protein and mRNA) would be important to establish in mice. This is especially critical to demonstrate in the disease model not only to correlate protein knockdown with restored function, but because the efficiency of Ad infection or gene editing could vary in diseased cells.</p></disp-quote><p>As described above (see Figure 3—figure supplement 1 and Figure 6), our revised manuscript addresses this concern with additional experiments to quantify Cas9, gRNA and COL8A2 (Figure 3—figure supplement 1 and Figure 6). With increasing Ad.Cas9.Col8a2gRNA dosage, (a) Cas9 and gRNA expression increased (Figure 6 a and b), (b) COL8A2 protein in corneal endothelium decreased (Figure 3 and Figure 3—figure supplement 1), (c) normal Col8a2 mRNA (no indel) rate decreased (Figure 6c), in both C57BL/6J and <italic>Col8a2</italic><sup>Q455K</sup> mice.</p><disp-quote content-type="editor-comment"><p>3. The authors note that the indel frequency, determined by deep sequencing, appears inconsistent with the observed protein knockdown as determined by immunostaining of tissue sections. However, while the indel frequency is determined quantitatively (~20-25%), but the protein and mRNA levels are not quantified. Is the half-life of wt and mutant COL8A2 known? The authors also report an editing normalized indel rate of 102% in endothelial cells. While the hypothesis of gDNA contamination from non-targeted tissue is likely true (supported by experimental evidence from Supplemental Figure 2), the method used for correction is insufficient to be used to report a true, corrected indel frequency.</p></disp-quote><p>We thank the reviewer for this comment and address it as follows. The half-life of corneal collagen is unknown. However, it is believed that corneal stroma collagen renews in 1-2 years. We quantified COL8A2 protein in corneal endothelium from the immunostaining sections (Figure 3—figure supplement 1a and b). We calculated the ratio using the staining intensity in corneal epithelium as a reference and normalized by background staining in isotype control (Figure 3—figure supplement 1c). The ratios of COL8A2 expression between corneal epithelium and endothelium were 80.1±18.7% (non-treated cornea), 51.1±29.2% (1.6 x 10<sup>6</sup> vg), 1.4±23.6% (6.3 x 10<sup>6</sup> vg) and 7.7±9.6% (25 x 10<sup>6</sup> vg). Also, we measured the normal Col8a2 (no indel) mRNA rate in Figure 6 (Please see Indel rate of Col8a2 mRNA in the above). From these observations, the calculated indel rate was within the expected range.</p><disp-quote content-type="editor-comment"><p>4. Overall what is the minimum/threshold % of endothelial cells that need to be edited to restore function? This information will be critical in designing vector dose and altering promoter strength/specificity to reduce off-target effects. While the impact of vector dose on COL8A2 expression knockdown is assessed, data pertaining to off-target effects at different doses are not presented.</p></disp-quote><p>This is an important point. In humans, corneal transplantation is considered when endothelial cell density dips below 1000 cells/mm<sup>2</sup> and is almost always required once it falls below 500 cells/mm<sup>2</sup>. Patients with early stage of FECD have 1000-2000 cells/mm<sup>2</sup>. Although 100% of editing would be preferred, even 30% editing will be enough to slow the progression of FECD, likely achieving a point of endothelial reserve sufficient to avoid corneal transplantation.</p><disp-quote content-type="editor-comment"><p>5. Does overexpression of spCas9, gRNA and knockdown of COL8A2 affect the expression of other genes in the endothelium? The authors analyze the impact of Ad dosing at the inflammatory level, but consequences of control vs treatment vector on endothelial cell gene expression have not been evaluated (e.g., Yu et al., Nat Commun, 2017).</p></disp-quote><p>We thank the reviewer for this insightful point. As noted in the reply to the editor’s comments (which noted that this assay is not required), future studies will explore this issue by RNAseq, and we have included a statement to this effect in the discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>This is an interesting study demonstrating the use of CRISPR/Cas9 to prevent development of Fuchs' corneal dystrophy in a mouse model in which the human mutation (Q455K / Q455K) was knocked into the Col8a2 gene. This gene mutation has been previously shown to induce early-onset Fuchs' dystrophy in patients. This is an important observation with translational potential to treat a subpopulation of patients with Fuchs' dystrophy.</p><p>In general, the data support the author's conclusion that Adenovirus-Cas9-gRNA restores the phenotype in adult post-mitotic cells.</p><p>I have a two major questions / issues:</p><p>1. The data presented in Figure 3 are critical to the paper and show that Ad-Cas9-Col8a2gRNA treatment reduces expression of the Col8A2 protein in corneal endothelial cells. However, there is no quantitative assessment of the protein reduction other than the images presented from three cross sections. Since Figure 2a indicates the transduction of the corneal endothelial cells is not evenly distributed, some type of quantitative assessment is needed for Figure 3, either measuring the antibody staining in numerous sections from several different corneas, or by western blot. This is necessary, even though there is quantitative assessment of the change in phenotype of the treated corneas (corneal endothelial cell density, morphology, and guttae-like lesion expression).</p></disp-quote><p>We agree with both reviewers on this point and have quantified COL8A2 expression in the Figure 3—figure supplement 1. Please see the above “COL8A2 protein quantification” in the response to the editor.</p><disp-quote content-type="editor-comment"><p>2. To demonstrate that Ad-Cas9-Col8a2gRNA treatment rescued corneal endothelial cell function in the mutant mice, the authors developed an assay that measured the ability of endothelial cell pump function to reduce swelling of the stroma after the corneas were induced to swell by adding hypertonic solutions. While this assay does measure pump function, there is a more direct measure of mutant corneal endothelial cells. The investigators that created the Col8A2 (Q455K / Q455K) mutant mice demonstrated the mutation caused an activation of UPR (unfolded protein response) as shown by an increase in Grp78 and Grp153 in corneal endothelial cells. In my opinion, demonstrating rescue of this function in the mutant mice would have been significantly more impressive.</p></disp-quote><p>We thank the reviewer for this comment, and as noted in the reply to the editor’s comments (which noted that this assay is not required), we plan to investigate UPR and other effects in future studies and have noted this in the discussion.</p></body></sub-article></article>